CD30	B-protein
is	O
a	O
CD40-inducible	B-protein
molecule	I-protein
that	O
negatively	O
regulates	O
CD40-mediated	B-protein
immunoglobulin	I-protein
class	O
switching	O
in	O
non-antigen-selected	B-cell_line
human	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

We	O
used	O
our	O
monoclonal	O
model	O
of	O
germinal	O
center	O
maturation	O
,	O
CL-01	B-cell_type
B	I-cell_type
cells	I-cell_type
,	O
to	O
investigate	O
the	O
role	O
of	O
CD30	B-protein
in	O
human	O
B	O
cell	O
differentiation	O
.	O

CL-01	B-cell_line
cells	I-cell_line
are	O
IgM	B-protein
+	O
IgD	B-protein
+	O
CD30	B-protein
+	O
and	O
switch	O
to	O
IgG	B-protein
,	O
IgA	B-protein
,	O
and	O
IgE	B-protein
when	O
exposed	O
to	O
CD40L	B-protein
and	O
IL-4	B-protein
.	O

Switching	O
is	O
hampered	O
by	O
CD30	B-protein
coengagement	O
,	O
possibly	O
through	O
interference	O
with	O
the	O
CD40	B-protein
-mediated	O
NF-kappaB	B-protein
-dependent	O
transcriptional	O
activation	O
of	O
downstream	B-DNA
C	I-DNA
(	I-DNA
H	I-DNA
)	I-DNA
genes	I-DNA
.	O

The	O
physiological	O
relevance	O
of	O
this	O
phenomenon	O
is	O
emphasized	O
by	O
similar	O
CD30	B-protein
-mediated	O
effects	O
in	O
naive	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Expression	O
of	O
CD30	B-protein
by	O
these	O
cells	O
is	O
induced	O
by	O
CD40L	B-protein
but	O
is	O
inhibited	O
by	O
B	O
cell	O
receptor	O
coengagement	O
and/or	O
exposure	O
to	O
IL-6	B-protein
and	O
IL-12	B-protein
.	O

Our	O
data	O
suggest	O
that	O
CD30	B-protein
critically	O
regulates	O
the	O
CD40	B-protein
-mediated	O
differentiation	O
of	O
non-antigen-selected	B-cell_line
human	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

iduosnuep	NULL
1oyny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
+	NULL
4	NULL
,	NULL
%	NULL
,	NULL
vic	NULL
``	NULL
``	NULL
~	NULL
-	NULL
HHS	NULL
Public	NULL
Access	NULL
Fa	NULL
Author	NULL
manuscript	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26	NULL
.	NULL

Published	NULL
in	NULL
final	NULL
edited	NULL
form	NULL
as	NULL
:	NULL
Immunity	NULL
.	NULL

1998	NULL
August	NULL
;	NULL
9	NULL
(	NULL
2	NULL
)	NULL
:	NULL
247-256	NULL
.	NULL

CD30	NULL
Is	NULL
a	NULL
CD40-Inducible	NULL
Molecule	NULL
that	NULL
Negatively	NULL
Regulates	NULL
CD40-Mediated	NULL
Immunoglobulin	NULL
Class	NULL
Switching	NULL
in	NULL
Non-Antigen-Selected	NULL
Human	NULL
B	NULL
Cells	NULL
Andrea	NULL
Cerutti®	NULL
,	NULL
Andras	NULL
Schaffer*	NULL
,	NULL
Shefali	NULL
Shah	NULL
``	NULL
,	NULL
Hong	NULL
Zan	NULL
``	NULL
,	NULL
Hsiou-Chi	NULL
Liout	NULL
,	NULL
Raymond	NULL
G.	NULL
Goodwin	NULL
$	NULL
,	NULL
and	NULL
Paolo	NULL
Casali	NULL
'	NULL
:	NULL
t-	NULL
!	NULL

!	NULL

*Division	NULL
of	NULL
Molecular	NULL
Immunology	NULL
,	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Cornell	NULL
University	NULL
Graduate	NULL
School	NULL
of	NULL
Medical	NULL
Sciences	NULL
,	NULL
New	NULL
York	NULL
,	NULL
New	NULL
York	NULL
10021	NULL
?	NULL

The	NULL
Immunology	NULL
Program	NULL
,	NULL
Cornell	NULL
University	NULL
Graduate	NULL
School	NULL
of	NULL
Medical	NULL
Sciences	NULL
,	NULL
New	NULL
York	NULL
,	NULL
New	NULL
York	NULL
10021	NULL
*Divigion	NULL
of	NULL
Immunology	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Cornell	NULL
University	NULL
Medical	NULL
College	NULL
,	NULL
New	NULL
York	NULL
,	NULL
New	NULL
York	NULL
10021	NULL
§lmmunex	NULL
Corporation	NULL
,	NULL
Seattle	NULL
,	NULL
Washington	NULL
,	NULL
98101	NULL
Summary	NULL
We	NULL
used	NULL
our	NULL
monoclonal	NULL
model	NULL
of	NULL
germinal	NULL
center	NULL
maturation	NULL
,	NULL
CL-O01	NULL
B	NULL
cells	NULL
,	NULL
to	NULL
investigate	NULL
the	NULL
role	NULL
of	NULL
CD30	NULL
in	NULL
human	NULL
B	NULL
cell	NULL
differentiation	NULL
.	NULL

CL-01	NULL
cells	NULL
are	NULL
Ig	NULL
M	NULL
*IgD*CD30*	NULL
and	NULL
switch	NULL
to	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
and	NULL
IgE	NULL
when	NULL
exposed	NULL
to	NULL
CD4O0L	NULL
and	NULL
IL-4	NULL
.	NULL

Switching	NULL
is	NULL
hampered	NULL
by	NULL
CD30	NULL
coengagement	NULL
,	NULL
possibly	NULL
through	NULL
interference	NULL
with	NULL
the	NULL
CD4O0-mediated	NULL
NF-xB-dependent	NULL
transcriptional	NULL
activation	NULL
of	NULL
downstream	NULL
Cy	NULL
genes	NULL
.	NULL

The	NULL
physiological	NULL
relevance	NULL
of	NULL
this	NULL
phenomenon	NULL
is	NULL
emphasized	NULL
by	NULL
similar	NULL
CD30-mediated	NULL
effects	NULL
in	NULL
naive	NULL
B	NULL
cells	NULL
.	NULL

Expression	NULL
of	NULL
CD30	NULL
by	NULL
these	NULL
cells	NULL
is	NULL
induced	NULL
by	NULL
CD4OL	NULL
but	NULL
is	NULL
inhibited	NULL
by	NULL
B	NULL
cell	NULL
receptor	NULL
coengagement	NULL
and/	NULL
or	NULL
exposure	NULL
to	NULL
IL-6	NULL
and	NULL
IL-12	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
that	NULL
CD30	NULL
critically	NULL
regulates	NULL
the	NULL
CD4O0-mediated	NULL
differentiation	NULL
of	NULL
non-antigen-selected	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

Introduction	NULL
Recent	NULL
findings	NULL
have	NULL
suggested	NULL
that	NULL
stimulation	NULL
of	NULL
B	NULL
lymphocytes	NULL
through	NULL
their	NULL
antigen	NULL
receptor	NULL
(	NULL
BCR	NULL
)	NULL
can	NULL
be	NULL
effectively	NULL
modulated	NULL
by	NULL
receptor	NULL
inhibitory	NULL
membrane-bound	NULL
molecules	NULL
,	NULL
as	NULL
exemplified	NULL
by	NULL
FeyRIIb	NULL
(	NULL
Takai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
antigen	NULL
(	NULL
Ag	NULL
)	NULL
-IgG	NULL
complexes	NULL
to	NULL
FeyRIIb	NULL
down-regulates	NULL
BCR-induced	NULL
B	NULL
cell	NULL
activation	NULL
and	NULL
would	NULL
modulate	NULL
the	NULL
response	NULL
of	NULL
B	NULL
cells	NULL
to	NULL
Ag	NULL
while	NULL
in	NULL
the	NULL
microenvironment	NULL
of	NULL
the	NULL
germinal	NULL
center	NULL
(	NULL
GC	NULL
)	NULL
,	NULL
thereby	NULL
dampening	NULL
or	NULL
terminating	NULL
a	NULL
specific	NULL
antibody	NULL
(	NULL
Ab	NULL
)	NULL
response	NULL
(	NULL
O'Rourke	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Integrated	NULL
inhibitory	NULL
signaling	NULL
systems	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
CD152	NULL
(	NULL
CTLA-4	NULL
)	NULL
down-regulates	NULL
the	NULL
responses	NULL
of	NULL
CD28-activated	NULL
T	NULL
cells	NULL
by	NULL
inhibiting	NULL
their	NULL
IL-2	NULL
production	NULL
(	NULL
Walunas	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
critical	NULL
negative	NULL
regulatory	NULL
role	NULL
of	NULL
CD152	NULL
in	NULL
T	NULL
cell	NULL
!	NULL

!	NULL

'To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
(	NULL
peasali	NULL
@	NULL
mail.med.cornell.edu	NULL
)	NULL
.	NULL

iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
2	NULL
responses	NULL
is	NULL
emphasized	NULL
by	NULL
the	NULL
massive	NULL
lymphoproliferation	NULL
and	NULL
multiorgan	NULL
tissue	NULL
destruction	NULL
in	NULL
CD152-deficient	NULL
mice	NULL
(	NULL
Tivol	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
Ag	NULL
and	NULL
cytokines	NULL
,	NULL
CD40	NULL
ligand	NULL
(	NULL
CD4O0L	NULL
,	NULL
CD154	NULL
)	NULL
provides	NULL
a	NULL
potent	NULL
stimulus	NULL
for	NULL
B	NULL
cells	NULL
.	NULL

CD4OL	NULL
on	NULL
T	NULL
cells	NULL
engages	NULL
CD40	NULL
on	NULL
naive	NULL
B	NULL
cells	NULL
to	NULL
induce	NULL
proliferation	NULL
,	NULL
Ig	NULL
class	NULL
switching	NULL
,	NULL
and	NULL
phenotypic	NULL
differentiation	NULL
(	NULL
Van	NULL
Kooten	NULL
and	NULL
Banchereau	NULL
,	NULL
1996	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
CD40	NULL
engagement	NULL
by	NULL
CD4OL	NULL
is	NULL
critical	NULL
for	NULL
B	NULL
cell	NULL
maturation	NULL
to	NULL
plasma	NULL
cell	NULL
and	NULL
memory	NULL
B	NULL
cell	NULL
in	NULL
the	NULL
GC	NULL
.	NULL

The	NULL
central	NULL
role	NULL
played	NULL
by	NULL
CD40	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
these	NULL
processes	NULL
is	NULL
exemplified	NULL
by	NULL
isotype	NULL
class	NULL
switching	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
other	NULL
stimuli	NULL
,	NULL
CD40	NULL
engagement	NULL
by	NULL
CD4O0L	NULL
triggers	NULL
transcriptional	NULL
activation	NULL
of	NULL
multiple	NULL
Cy	NULL
genes	NULL
and	NULL
induces	NULL
abundant	NULL
B	NULL
cell	NULL
secretion	NULL
of	NULL
transforming	NULL
growth	NULL
factor	NULL
B	NULL
and	NULL
IL-10	NULL
,	NULL
which	NULL
mediate	NULL
switch	NULL
DNA	NULL
recombination	NULL
and	NULL
,	NULL
eventually	NULL
,	NULL
further	NULL
differentiation	NULL
(	NULL
Jumper	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998a	NULL
)	NULL
.	NULL

Surface	NULL
receptors	NULL
that	NULL
facilitate	NULL
or	NULL
enhance	NULL
CD40-dependent	NULL
B	NULL
cell	NULL
responses	NULL
have	NULL
been	NULL
identified	NULL
,	NULL
including	NULL
BCR	NULL
and	NULL
IL-2	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
IL-10	NULL
receptors	NULL
(	NULL
Van	NULL
Kooten	NULL
and	NULL
Banchereau	NULL
,	NULL
1996	NULL
)	NULL
,	NULL
but	NULL
surface	NULL
molecules	NULL
or	NULL
signaling	NULL
pathways	NULL
that	NULL
down-regulate	NULL
CD40-mediated	NULL
responses	NULL
have	NULL
not	NULL
been	NULL
so	NULL
far	NULL
described	NULL
.	NULL

Here	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
role	NULL
of	NULL
CD30	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
CD40-dependent	NULL
Ig	NULL
class	NULL
switching	NULL
.	NULL

CD30	NULL
is	NULL
a	NULL
120	NULL
kDa	NULL
type	NULL
I	NULL
transmembrane	NULL
glycoprotein	NULL
with	NULL
sequence	NULL
homology	NULL
to	NULL
members	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
(	NULL
TNFR	NULL
)	NULL
superfamily	NULL
,	NULL
including	NULL
CD27	NULL
,	NULL
CD40	NULL
,	NULL
CD95	NULL
(	NULL
Fas	NULL
)	NULL
,	NULL
CD120a	NULL
(	NULL
TNF-R1	NULL
)	NULL
,	NULL
CD120b	NULL
(	NULL
TNF-R2	NULL
)	NULL
,	NULL
CD134	NULL
(	NULL
OX40	NULL
)	NULL
,	NULL
and	NULL
CDw137	NULL
(	NULL
4-1BB	NULL
)	NULL
(	NULL
Smith	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Originally	NULL
identified	NULL
in	NULL
Hodgkin	NULL
and	NULL
Reed-Sternberg	NULL
neoplastic	NULL
cells	NULL
(	NULL
Stein	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
,	NULL
CD30	NULL
subsequently	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
expressed	NULL
in	NULL
non-Hodgkin	NULL
B	NULL
cell	NULL
lymphomas	NULL
as	NULL
well	NULL
as	NULL
in	NULL
virally	NULL
transformed	NULL
B	NULL
cells	NULL
(	NULL
Schwarting	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Diirkop	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

While	NULL
surface	NULL
CD30	NULL
is	NULL
virtually	NULL
absent	NULL
in	NULL
normal	NULL
circulating	NULL
B	NULL
lymphocytes	NULL
,	NULL
it	NULL
has	NULL
been	NULL
detected	NULL
in	NULL
a	NULL
small	NULL
population	NULL
of	NULL
B	NULL
lymphocytes	NULL
surrounding	NULL
the	NULL
GCs	NULL
of	NULL
secondary	NULL
lymphoid	NULL
organs	NULL
(	NULL
Stein	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Schwarting	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
,	NULL
together	NULL
with	NULL
reports	NULL
showing	NULL
the	NULL
expression	NULL
of	NULL
CD30L	NULL
(	NULL
CD153	NULL
)	NULL
by	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
Smith	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
suggests	NULL
that	NULL
CD30	NULL
is	NULL
involved	NULL
in	NULL
B	NULL
:	NULL
T	NULL
cell	NULL
cognate	NULL
interaction	NULL
(	NULL
Clark	NULL
and	NULL
Ledbetter	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
physiological	NULL
stimuli	NULL
that	NULL
would	NULL
induce	NULL
CD30	NULL
expression	NULL
in	NULL
B	NULL
cells	NULL
and	NULL
the	NULL
role	NULL
of	NULL
CD30	NULL
in	NULL
B	NULL
cell	NULL
development	NULL
remain	NULL
to	NULL
be	NULL
defined	NULL
.	NULL

Our	NULL
choice	NULL
of	NULL
CD30	NULL
as	NULL
a	NULL
possible	NULL
modulator	NULL
of	NULL
CD40-driven	NULL
B	NULL
cell	NULL
responses	NULL
has	NULL
been	NULL
suggested	NULL
by	NULL
the	NULL
finding	NULL
that	NULL
CD30	NULL
engagement	NULL
down-regulates	NULL
the	NULL
CD40-mediated	NULL
induction	NULL
of	NULL
germline	NULL
Is-Cs	NULL
transcripts	NULL
in	NULL
a	NULL
human	NULL
lymphoblastoid	NULL
B	NULL
cell	NULL
line	NULL
(	NULL
Jumper	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
,	NULL
1996	NULL
)	NULL
and	NULL
by	NULL
the	NULL
demonstration	NULL
that	NULL
an	NULL
element	NULL
of	NULL
the	NULL
CD30	NULL
receptor	NULL
signaling	NULL
complex	NULL
inhibits	NULL
the	NULL
activation	NULL
of	NULL
NF-xB	NULL
(	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
,	NULL
a	NULL
crucial	NULL
component	NULL
of	NULL
the	NULL
CD40	NULL
signaling	NULL
pathway	NULL
(	NULL
Kehry	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
CD4O0L	NULL
is	NULL
expressed	NULL
mainly	NULL
by	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
Armitage	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
,	NULL
whereas	NULL
CD30L	NULL
is	NULL
expressed	NULL
mainly	NULL
by	NULL
activated	NULL
CD8*	NULL
T	NULL
cells	NULL
(	NULL
Smith	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
these	NULL
two	NULL
molecules	NULL
and	NULL
their	NULL
receptors	NULL
may	NULL
have	NULL
antagonistic	NULL
regulatory	NULL
roles	NULL
.	NULL

In	NULL
these	NULL
studies	NULL
we	NULL
show	NULL
that	NULL
naive	NULL
surface	NULL
(	NULL
s	NULL
)	NULL
Ig	NULL
M*	NULL
sIgD*CD30-	NULL
B	NULL
cells	NULL
express	NULL
CD30	NULL
upon	NULL
CD40	NULL
engagement	NULL
by	NULL
CD4OL	NULL
and	NULL
are	NULL
thereafter	NULL
susceptible	NULL
to	NULL
CD30-dependent	NULL
inhibition	NULL
of	NULL
switching	NULL
to	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
and	NULL
IgE	NULL
.	NULL

This	NULL
inhibition	NULL
results	NULL
from	NULL
an	NULL
interference	NULL
with	NULL
the	NULL
CD40-mediated	NULL
NF-xB-dependent	NULL
Cy	NULL
gene	NULL
transcriptional	NULL
activation	NULL
,	NULL
as	NULL
suggested	NULL
by	NULL
the	NULL
functional	NULL
analysis	NULL
of	NULL
the	NULL
human	NULL
Cy3	NULL
promoter	NULL
.	NULL

By	NULL
showing	NULL
that	NULL
BCR	NULL
coengagement	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
3	NULL
counteracts	NULL
the	NULL
CD4O0-mediated	NULL
CD30	NULL
induction	NULL
,	NULL
our	NULL
findings	NULL
suggest	NULL
that	NULL
CD30	NULL
negatively	NULL
modulates	NULL
the	NULL
CD4O0-dependent	NULL
differentiation	NULL
of	NULL
non-	NULL
Ag-selected	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

Results	NULL
CD30	NULL
Engagement	NULL
Hampers	NULL
CD40-Mediated	NULL
Germline	NULL
Transcription	NULL
of	NULL
Downstream	NULL
Cp	NULL
Genes	NULL
and	NULL
Switching	NULL
to	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
and	NULL
IgE	NULL
in	NULL
Human	NULL
sigM+slIgD*	NULL
B	NULL
Cells	NULL
We	NULL
have	NULL
recently	NULL
identified	NULL
a	NULL
human	NULL
monoclonal	NULL
B	NULL
cell	NULL
line	NULL
,	NULL
CL-O1	NULL
cells	NULL
,	NULL
that	NULL
expresses	NULL
sIgM	NULL
and	NULL
sIgD	NULL
and	NULL
,	NULL
upon	NULL
exposure	NULL
to	NULL
CD4OL	NULL
and	NULL
IL-4	NULL
,	NULL
switches	NULL
to	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
and	NULL
IgE	NULL
(	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

CD30	NULL
expression	NULL
by	NULL
unstimulated	NULL
CL-O01	NULL
cells	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
enabled	NULL
us	NULL
to	NULL
address	NULL
the	NULL
potential	NULL
role	NULL
of	NULL
this	NULL
molecule	NULL
in	NULL
the	NULL
modulation	NULL
of	NULL
CD4O0-induced	NULL
germline	NULL
Iy-Cy	NULL
and	NULL
productive	NULL
VgDJy-Cy	NULL
transcription	NULL
as	NULL
well	NULL
as	NULL
Ig	NULL
DNA	NULL
switch	NULL
recombination	NULL
.	NULL

To	NULL
mimic	NULL
the	NULL
engagement	NULL
of	NULL
CD30	NULL
by	NULL
its	NULL
natural	NULL
ligand	NULL
,	NULL
the	NULL
MAb	NULL
M44	NULL
(	NULL
IgG1	NULL
)	NULL
,	NULL
an	NULL
agonistic	NULL
mouse	NULL
MAb	NULL
to	NULL
human	NULL
CD30	NULL
(	NULL
Smith	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Gruss	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Del	NULL
Prete	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
,	NULL
was	NULL
immobilized	NULL
onto	NULL
polystyrene	NULL
plates	NULL
at	NULL
5	NULL
ug/ml	NULL
.	NULL

Immobilized	NULL
mouse	NULL
MAb	NULL
MOPC-21	NULL
(	NULL
IgG1	NULL
)	NULL
with	NULL
irrelevant	NULL
binding	NULL
activity	NULL
was	NULL
used	NULL
as	NULL
control	NULL
.	NULL

In	NULL
parallel	NULL
experiments	NULL
,	NULL
CD30	NULL
was	NULL
engaged	NULL
by	NULL
CD3O0L	NULL
as	NULL
presented	NULL
by	NULL
CD8*CD30L*	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
induce	NULL
Ig	NULL
class	NULL
switching	NULL
,	NULL
CL-O1	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
soluble	NULL
human	NULL
trimeric	NULL
CD4O0L/leucin	NULL
zipper	NULL
fusion	NULL
protein	NULL
(	NULL
htCD4O0L	NULL
)	NULL
(	NULL
0.5	NULL
ug/ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-4	NULL
(	NULL
100	NULL
U/ml	NULL
)	NULL
.	NULL

CL-O01	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
medium	NULL
only	NULL
or	NULL
in	NULL
medium	NULL
containing	NULL
IL-4	NULL
alone	NULL
,	NULL
htCD4O0L	NULL
alone	NULL
,	NULL
or	NULL
htCD40L	NULL
and	NULL
IL-4	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
immobilized	NULL
MOPC-21	NULL
or	NULL
anti-CD30	NULL
MAbs	NULL
.	NULL

Ig	NULL
class	NULL
switching	NULL
was	NULL
assessed	NULL
by	NULL
the	NULL
analysis	NULL
of	NULL
germline	NULL
In-Cy	NULL
and	NULL
productive	NULL
VgDJgu	NULL
,	NULL
y1	NULL
,	NULL
y2	NULL
,	NULL
y3	NULL
,	NULL
y4	NULL
,	NULL
al	NULL
,	NULL
a2	NULL
,	NULL
and	NULL
&	NULL
transcripts	NULL
,	NULL
which	NULL
were	NULL
amplified	NULL
from	NULL
CL-O1	NULL
cells	NULL
cultured	NULL
for	NULL
2	NULL
and	NULL
5	NULL
days	NULL
,	NULL
respectively	NULL
.	NULL

CL-01	NULL
cells	NULL
expressed	NULL
only	NULL
VgDJy-Cu	NULL
transcripts	NULL
(	NULL
Figure	NULL
1D	NULL
)	NULL
,	NULL
but	NULL
failed	NULL
to	NULL
express	NULL
In-Cy	NULL
and	NULL
VgDJy-Cy1	NULL
,	NULL
-Cy2	NULL
,	NULL
-Cy3	NULL
,	NULL
-Cy4	NULL
,	NULL
-Cal	NULL
,	NULL
-Ca2	NULL
,	NULL
and	NULL
-Cs	NULL
transcripts	NULL
upon	NULL
incubation	NULL
with	NULL
MOPC-21	NULL
or	NULL
anti-CD30	NULL
MAbs	NULL
with	NULL
or	NULL
without	NULL
IL-4	NULL
(	NULL
Figure	NULL
1C	NULL
)	NULL
.	NULL

Upon	NULL
exposure	NULL
to	NULL
htCD4O0L	NULL
,	NULL
CL-O1	NULL
cells	NULL
expressed	NULL
Iu-Cy	NULL
,	NULL
Iy1-Cy1	NULL
,	NULL
I1y2-Cy2	NULL
,	NULL
1y3-Cy3	NULL
,	NULL
and	NULL
Ia1-Cal	NULL
as	NULL
well	NULL
as	NULL
VgDJy-Cy1	NULL
and	NULL
VgDJy-Cal	NULL
transcripts	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
IL-4	NULL
to	NULL
htCD40L	NULL
extended	NULL
germ-line	NULL
transcription	NULL
to	NULL
1y4-Cy4	NULL
,	NULL
Ia2-Ca2	NULL
,	NULL
Is-Cs	NULL
,	NULL
and	NULL
productive	NULL
transcription	NULL
to	NULL
VgDJy-Cy2	NULL
,	NULL
-Cy3	NULL
,	NULL
-Cy4	NULL
,	NULL
-Ca2	NULL
,	NULL
and	NULL
-Cs	NULL
.	NULL

CD30	NULL
coengagement	NULL
by	NULL
anti-CD30	NULL
MAb	NULL
or	NULL
CD3O0L	NULL
on	NULL
T	NULL
cells	NULL
virtually	NULL
abrogated	NULL
the	NULL
expression	NULL
of	NULL
both	NULL
htCD40L~	NULL
and	NULL
htCD4O0L	NULL
and	NULL
IL-4-induced	NULL
and	NULL
VgDJy-Cy	NULL
transcripts	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
selective	NULL
,	NULL
as	NULL
VgDJy-Cu	NULL
transcription	NULL
was	NULL
spared	NULL
(	NULL
Figure	NULL
1D	NULL
)	NULL
,	NULL
and	NULL
was	NULL
comparably	NULL
induced	NULL
by	NULL
fixed	NULL
CD8*	NULL
T	NULL
cells	NULL
expressing	NULL
CD3O0L	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
specific	NULL
extrachromosomal	NULL
DNA	NULL
recombination	NULL
products	NULL
could	NULL
be	NULL
readily	NULL
detected	NULL
in	NULL
CL-O1	NULL
cells	NULL
exposed	NULL
to	NULL
htCD4O0L	NULL
and	NULL
IL-4	NULL
(	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
,	NULL
but	NULL
not	NULL
after	NULL
CD30	NULL
coengagement	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
,	NULL
CD30	NULL
occupancy	NULL
hampers	NULL
CD4OL	NULL
and	NULL
IL-4-induced	NULL
Cp	NULL
gene	NULL
transcriptional	NULL
activation	NULL
and	NULL
switch	NULL
DNA	NULL
recombination	NULL
.	NULL

The	NULL
CD30-dependent	NULL
inhibitory	NULL
effect	NULL
on	NULL
CD4O	NULL
signaling	NULL
was	NULL
not	NULL
related	NULL
to	NULL
the	NULL
down-regulation	NULL
of	NULL
CD40	NULL
expression	NULL
by	NULL
CL-O01	NULL
cells	NULL
,	NULL
as	NULL
these	NULL
cells	NULL
expressed	NULL
CD40	NULL
at	NULL
comparable	NULL
density	NULL
upon	NULL
incubation	NULL
with	NULL
control	NULL
MOPC-21	NULL
or	NULL
anti-CD30	NULL
MAbs	NULL
for	NULL
2	NULL
or	NULL
5	NULL
days	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
CD30	NULL
engagement	NULL
did	NULL
not	NULL
hamper	NULL
the	NULL
CD4O0-mediated	NULL
up-regulation	NULL
of	NULL
surface	NULL
CD23	NULL
(	NULL
FesRIN	NULL
)	NULL
,	NULL
CD54	NULL
(	NULL
ICAM-1	NULL
)	NULL
,	NULL
CD80	NULL
(	NULL
B7.1	NULL
)	NULL
,	NULL
or	NULL
CD95	NULL
(	NULL
Fas	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
4	NULL
further	NULL
suggesting	NULL
that	NULL
CD30	NULL
signaling	NULL
negatively	NULL
regulates	NULL
the	NULL
expression	NULL
of	NULL
some	NULL
,	NULL
but	NULL
not	NULL
all	NULL
,	NULL
CD40-inducible	NULL
genes	NULL
.	NULL

Naive	NULL
B	NULL
Cells	NULL
Express	NULL
CD30	NULL
and	NULL
GC	NULL
Phenotypic	NULL
Traits	NULL
When	NULL
Exposed	NULL
to	NULL
CD40L	NULL
sIgM	NULL
*sIgD*	NULL
CL-01	NULL
cells	NULL
constitutively	NULL
express	NULL
CD30	NULL
,	NULL
but	NULL
only	NULL
a	NULL
few	NULL
GC	NULL
B	NULL
cells	NULL
express	NULL
this	NULL
member	NULL
of	NULL
the	NULL
TNFR	NULL
family	NULL
in	NULL
vivo	NULL
(	NULL
Schwarting	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

We	NULL
analyzed	NULL
the	NULL
ability	NULL
of	NULL
sIgM	NULL
*sIgD*	NULL
naive	NULL
B	NULL
cells	NULL
to	NULL
express	NULL
CD30	NULL
mRNA	NULL
and	NULL
surface	NULL
CD30	NULL
following	NULL
CD40	NULL
engagement	NULL
by	NULL
CD4O0L	NULL
.	NULL

Freshly	NULL
isolated	NULL
naive	NULL
B	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
or	NULL
naive	NULL
B	NULL
cells	NULL
incubated	NULL
for	NULL
3	NULL
days	NULL
in	NULL
medium	NULL
only	NULL
expressed	NULL
CD19	NULL
(	NULL
a	NULL
pan-B	NULL
cell	NULL
marker	NULL
)	NULL
but	NULL
lacked	NULL
surface	NULL
CD30	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

Upon	NULL
incubation	NULL
with	NULL
htCD4O0L	NULL
(	NULL
0.5	NULL
ug/ml	NULL
!	NULL
)	NULL

,	NULL
about	NULL
80	NULL
%	NULL
of	NULL
B	NULL
cells	NULL
expressed	NULL
surface	NULL
CD30	NULL
and	NULL
CD30	NULL
mRNA	NULL
as	NULL
well	NULL
as	NULL
the	NULL
GC	NULL
markers	NULL
CD71	NULL
(	NULL
transferrin	NULL
receptor	NULL
)	NULL
,	NULL
CD80	NULL
,	NULL
CD86	NULL
(	NULL
B7.2	NULL
)	NULL
,	NULL
and	NULL
CD95	NULL
(	NULL
Fas	NULL
)	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
.	NULL

A	NULL
time	NULL
course	NULL
analysis	NULL
showed	NULL
that	NULL
surface	NULL
CD30	NULL
expression	NULL
occurred	NULL
as	NULL
early	NULL
as	NULL
24	NULL
hr	NULL
following	NULL
CD40	NULL
engagement	NULL
and	NULL
peaked	NULL
after	NULL
4	NULL
days	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Naive	NULL
B	NULL
cells	NULL
incubated	NULL
with	NULL
IL-1	NULL
$	NULL
3	NULL
,	NULL
IL-2	NULL
,	NULL
IL-4	NULL
,	NULL
IL-6	NULL
,	NULL
IL-7	NULL
,	NULL
IL-10	NULL
,	NULL
IL-12	NULL
,	NULL
IL-13	NULL
,	NULL
interferon-y	NULL
(	NULL
IFNy	NULL
)	NULL
,	NULL
IFNa	NULL
,	NULL
TGFB1	NULL
,	NULL
TNFa	NULL
,	NULL
lymphotoxin-B	NULL
(	NULL
LTB	NULL
)	NULL
,	NULL
or	NULL
immobilized	NULL
anti-x	NULL
and	NULL
anti-A	NULL
chain	NULL
(	NULL
anti-BCR	NULL
)	NULL
MAbs	NULL
(	NULL
2	NULL
ug/ml	NULL
each	NULL
)	NULL
did	NULL
not	NULL
express	NULL
surface	NULL
CD30	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
or	NULL
CD30	NULL
mRNA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
unless	NULL
CD40	NULL
was	NULL
engaged	NULL
by	NULL
htCD4O0L	NULL
.	NULL

Thus	NULL
,	NULL
naive	NULL
B	NULL
cells	NULL
express	NULL
CD30	NULL
upon	NULL
exposure	NULL
to	NULL
CD40L	NULL
,	NULL
but	NULL
not	NULL
to	NULL
other	NULL
stimuli	NULL
,	NULL
including	NULL
BCR	NULL
engagement	NULL
and	NULL
a	NULL
variety	NULL
of	NULL
cytokines	NULL
.	NULL

CD30	NULL
Engagement	NULL
Hampers	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
and	NULL
IgE	NULL
Secretion	NULL
by	NULL
Naive	NULL
B	NULL
Cells	NULL
Induced	NULL
by	NULL
CD40L	NULL
and	NULL
Appropriate	NULL
Cytokines	NULL
We	NULL
extended	NULL
our	NULL
findings	NULL
to	NULL
normal	NULL
human	NULL
B	NULL
cells	NULL
by	NULL
assessing	NULL
IgM	NULL
,	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
and	NULL
IgE	NULL
secretion	NULL
in	NULL
freshly	NULL
isolated	NULL
sIgM	NULL
*sIgD*	NULL
B	NULL
cells	NULL
cultured	NULL
in	NULL
medium	NULL
only	NULL
or	NULL
in	NULL
medium	NULL
containing	NULL
0.5	NULL
ug/ml	NULL
of	NULL
htCD40L	NULL
,	NULL
100	NULL
U/ml	NULL
of	NULL
IL-4	NULL
,	NULL
200	NULL
ng/ml	NULL
of	NULL
IL-10	NULL
(	NULL
this	NULL
cytokine	NULL
was	NULL
added	NULL
to	NULL
increase	NULL
the	NULL
B	NULL
cell	NULL
proliferation	NULL
)	NULL
,	NULL
and	NULL
0.5	NULL
ng/ml	NULL
of	NULL
TGFBI	NULL
(	NULL
this	NULL
cytokine	NULL
was	NULL
used	NULL
to	NULL
optimize	NULL
the	NULL
IgA	NULL
secretion	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
control	NULL
MOPC-21	NULL
or	NULL
agonistic	NULL
anti-CD30	NULL
immobilized	NULL
MAbs	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
.	NULL

Naive	NULL
B	NULL
cells	NULL
were	NULL
seeded	NULL
onto	NULL
MOPC-21	NULL
or	NULL
anti-CD30	NULL
MAb	NULL
coated	NULL
plates	NULL
for	NULL
an	NULL
8	NULL
day	NULL
culture	NULL
after	NULL
preincubation	NULL
in	NULL
medium	NULL
only	NULL
or	NULL
in	NULL
medium	NULL
containing	NULL
htCD4O0L	NULL
to	NULL
up-regulate	NULL
CD30	NULL
expression	NULL
.	NULL

Upon	NULL
exposure	NULL
to	NULL
htCD4O0L	NULL
and	NULL
cytokines	NULL
,	NULL
B	NULL
cells	NULL
increased	NULL
IgM	NULL
secretion	NULL
and	NULL
produced	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
and	NULL
IgE	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
MOPC-21	NULL
MAb	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
our	NULL
findings	NULL
in	NULL
CL-O1	NULL
cells	NULL
,	NULL
this	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
and	NULL
IgE	NULL
,	NULL
but	NULL
not	NULL
IgM	NULL
,	NULL
secretion	NULL
was	NULL
significantly	NULL
decreased	NULL
when	NULL
MOPC-21	NULL
MAb	NULL
was	NULL
substituted	NULL
with	NULL
anti-CD30	NULL
MAb	NULL
.	NULL

This	NULL
CD30-mediated	NULL
inhibitory	NULL
effect	NULL
was	NULL
not	NULL
related	NULL
to	NULL
a	NULL
failure	NULL
of	NULL
CD4O0L	NULL
to	NULL
engage	NULL
appropriate	NULL
numbers	NULL
of	NULL
CD40	NULL
molecules	NULL
,	NULL
since	NULL
CD30-stimulated	NULL
B	NULL
cells	NULL
did	NULL
not	NULL
down-regulate	NULL
the	NULL
expression	NULL
of	NULL
CD40	NULL
as	NULL
compared	NULL
to	NULL
unstimulated	NULL
B	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
members	NULL
of	NULL
the	NULL
TNFR	NULL
superfamily	NULL
can	NULL
be	NULL
involved	NULL
in	NULL
cell	NULL
death	NULL
by	NULL
apoptosis	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
percentage	NULL
of	NULL
viable	NULL
B	NULL
cells	NULL
after	NULL
incubation	NULL
with	NULL
MOPC-21	NULL
or	NULL
anti-CD30	NULL
MAbs	NULL
by	NULL
trypan	NULL
blue	NULL
dye	NULL
exclusion	NULL
.	NULL

These	NULL
experiments	NULL
showed	NULL
that	NULL
the	NULL
survival	NULL
of	NULL
normal	NULL
B	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
CL-O1	NULL
cells	NULL
is	NULL
comparable	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
CD30	NULL
ligation	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

Ig	NULL
class	NULL
switching	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
be	NULL
linked	NULL
to	NULL
B	NULL
cell	NULL
proliferation	NULL
(	NULL
Hodgkin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

We	NULL
verified	NULL
whether	NULL
CD30	NULL
signaling	NULL
reduces	NULL
CD4O0L-induced	NULL
DNA	NULL
synthesis	NULL
in	NULL
naive	NULL
B	NULL
cells	NULL
cultured	NULL
for	NULL
5	NULL
days	NULL
as	NULL
above	NULL
.	NULL

B	NULL
cells	NULL
incubated	NULL
with	NULL
control	NULL
MOPC-21	NULL
or	NULL
anti	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
5	NULL
CD30	NULL
MAb	NULL
incorporated	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
(	NULL
TdR	NULL
)	NULL
at	NULL
similar	NULL
rates	NULL
in	NULL
response	NULL
to	NULL
htCD40L	NULL
and/or	NULL
cytokines	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
CL-O1	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
CD30	NULL
engagement	NULL
negatively	NULL
regulates	NULL
Ig	NULL
class	NULL
switching	NULL
and	NULL
secretion	NULL
,	NULL
but	NULL
not	NULL
proliferation	NULL
,	NULL
in	NULL
normal	NULL
B	NULL
cells	NULL
induced	NULL
by	NULL
CD4O0L	NULL
and	NULL
appropriate	NULL
cytokines	NULL
.	NULL

BCR	NULL
Engagement	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
IL-12	NULL
Down-Regulate	NULL
CD40L-Induced	NULL
Expression	NULL
of	NULL
Surface	NULL
CD30	NULL
by	NULL
Naive	NULL
B	NULL
Cells	NULL
Despite	NULL
the	NULL
massive	NULL
proportion	NULL
of	NULL
CD4O0-responsive	NULL
B	NULL
cells	NULL
,	NULL
only	NULL
a	NULL
few	NULL
B	NULL
cells	NULL
express	NULL
surface	NULL
CD30	NULL
in	NULL
vivo	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
CD40-dependent	NULL
generation	NULL
of	NULL
CD30*	NULL
B	NULL
cells	NULL
is	NULL
tightly	NULL
regulated	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
stimuli	NULL
possibly	NULL
involved	NULL
in	NULL
the	NULL
negative	NULL
regulation	NULL
of	NULL
CD40L-induced	NULL
CD30	NULL
expression	NULL
,	NULL
naive	NULL
B	NULL
cells	NULL
were	NULL
cocultured	NULL
for	NULL
3	NULL
days	NULL
with	NULL
htCD4OL	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
above	NULL
reported	NULL
cytokines	NULL
and/or	NULL
immobilized	NULL
anti-x	NULL
and	NULL
anti-A	NULL
chain	NULL
(	NULL
anti-BCR	NULL
)	NULL
MAbs	NULL
(	NULL
2	NULL
ug/ml	NULL
each	NULL
)	NULL
as	NULL
a	NULL
surrogate	NULL
of	NULL
Ag	NULL
.	NULL

Most	NULL
of	NULL
these	NULL
stimuli	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
CD30	NULL
,	NULL
but	NULL
BCR	NULL
engagement	NULL
or	NULL
,	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
,	NULL
IL-6	NULL
or	NULL
IL-12	NULL
significantly	NULL
reduced	NULL
the	NULL
proportion	NULL
of	NULL
CD40L-induced	NULL
CD30*	NULL
B	NULL
cells	NULL
without	NULL
affecting	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
GC	NULL
markers	NULL
CD71	NULL
,	NULL
CD80	NULL
,	NULL
CD86	NULL
,	NULL
and	NULL
CD95	NULL
(	NULL
Figures	NULL
2C	NULL
and	NULL
3	NULL
)	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
anti-BCR	NULL
MAbs	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
IL-12	NULL
reduced	NULL
by	NULL
up	NULL
to	NULL
80	NULL
%	NULL
the	NULL
CD40-dependent	NULL
CD30	NULL
expression	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
,	NULL
but	NULL
not	NULL
that	NULL
of	NULL
the	NULL
above	NULL
GC	NULL
molecules	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
this	NULL
finding	NULL
,	NULL
anti-BCR	NULL
MAbs	NULL
prevented	NULL
the	NULL
CD30-dependent	NULL
inhibition	NULL
of	NULL
Ig	NULL
class	NULL
switching	NULL
in	NULL
naive	NULL
B	NULL
cells	NULL
cultured	NULL
with	NULL
CD4OL	NULL
and	NULL
appropriate	NULL
cytokines	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
normal	NULL
B	NULL
cells	NULL
,	NULL
CD4O0L-induced	NULL
CD30	NULL
expression	NULL
is	NULL
negatively	NULL
regulated	NULL
by	NULL
BCR	NULL
coengagement	NULL
and	NULL
exposure	NULL
to	NULL
IL-6	NULL
and/or	NULL
IL-12	NULL
.	NULL

CD30	NULL
Engagement	NULL
Hampers	NULL
CD40-Mediated	NULL
Transcriptional	NULL
Activation	NULL
of	NULL
the	NULL
Human	NULL
Cy3	NULL
Germline	NULL
Gene	NULL
Promoter	NULL
We	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
Cy3	NULL
germline	NULL
gene	NULL
is	NULL
regulated	NULL
by	NULL
the	NULL
evolutionary	NULL
conserved	NULL
sequence	NULL
(	NULL
ECS	NULL
)	NULL
that	NULL
lies	NULL
5	NULL
``	NULL
of	NULL
the	NULL
corresponding	NULL
Iy3	NULL
region	NULL
and	NULL
is	NULL
synergistically	NULL
induced	NULL
by	NULL
CD4OL	NULL
and	NULL
IL-4	NULL
(	NULL
Schaffer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

The	NULL
CD40-mediated	NULL
activation	NULL
of	NULL
this	NULL
cis	NULL
regulatory	NULL
gene	NULL
sequence	NULL
impinges	NULL
on	NULL
a	NULL
responsive	NULL
element	NULL
(	NULL
RE	NULL
)	NULL
that	NULL
consists	NULL
of	NULL
two	NULL
tandemly	NULL
arrayed	NULL
NF-KB	NULL
binding	NULL
sites	NULL
.	NULL

To	NULL
verify	NULL
whether	NULL
the	NULL
CD30-mediated	NULL
inhibition	NULL
of	NULL
the	NULL
CD40-dependent	NULL
Cy3	NULL
germline	NULL
gene	NULL
transcription	NULL
(	NULL
Figure	NULL
1C	NULL
)	NULL
was	NULL
due	NULL
to	NULL
an	NULL
interference	NULL
with	NULL
the	NULL
Cy3	NULL
gene	NULL
transcriptional	NULL
activation	NULL
,	NULL
CL-01	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
an	NULL
ECS-Iy3-pGL3	NULL
luciferase	NULL
gene	NULL
reporter	NULL
vector	NULL
and	NULL
then	NULL
cultured	NULL
with	NULL
htCD4O0L	NULL
(	NULL
0.5	NULL
ug/ml	NULL
)	NULL
and/or	NULL
IL-4	NULL
(	NULL
500	NULL
U/ml	NULL
!	NULL
)	NULL

in	NULL
the	NULL
presence	NULL
of	NULL
immobilized	NULL
control	NULL
MOPC-21	NULL
or	NULL
anti-CD30	NULL
MAbs	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
.	NULL

After	NULL
24	NULL
hr	NULL
,	NULL
the	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
these	NULL
induced	NULL
CL-O1	NULL
cells	NULL
and	NULL
expressed	NULL
as	NULL
fold	NULL
induction	NULL
compared	NULL
to	NULL
the	NULL
basal	NULL
activity	NULL
of	NULL
cells	NULL
cultured	NULL
in	NULL
medium	NULL
only	NULL
.	NULL

The	NULL
Cy3	NULL
promoter	NULL
was	NULL
activated	NULL
by	NULL
htCD4O0L	NULL
or	NULL
IL-4	NULL
,	NULL
and	NULL
this	NULL
activation	NULL
was	NULL
synergistically	NULL
increased	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
these	NULL
stimuli	NULL
(	NULL
Figure	NULL
5A	NULL
)	NULL
.	NULL

Anti-CD30	NULL
,	NULL
but	NULL
not	NULL
MOPC-21	NULL
MAbs	NULL
,	NULL
reduced	NULL
by	NULL
about	NULL
50	NULL
%	NULL
the	NULL
activation	NULL
induced	NULL
by	NULL
htCD4OL	NULL
alone	NULL
or	NULL
htCD4O0L	NULL
and	NULL
IL-4	NULL
,	NULL
but	NULL
not	NULL
that	NULL
elicited	NULL
by	NULL
IL-4	NULL
alone	NULL
.	NULL

This	NULL
inhibition	NULL
was	NULL
also	NULL
evident	NULL
when	NULL
CL-O01	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
an	NULL
isolated	NULL
ECS-Iy3	NULL
CD4ORE	NULL
included	NULL
in	NULL
a	NULL
SV40-pGL3	NULL
minimal	NULL
promoter	NULL
plasmid	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
saturating	NULL
amounts	NULL
of	NULL
neutralizing	NULL
anti-IFNy	NULL
(	NULL
Figures	NULL
5A	NULL
and	NULL
5B	NULL
)	NULL
,	NULL
anti-IL-6	NULL
,	NULL
anti-IL-10	NULL
,	NULL
or	NULL
anti-	NULL
Abs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
did	NULL
not	NULL
reverse	NULL
the	NULL
above	NULL
reported	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
6	NULL
CD30-dependent	NULL
inhibition	NULL
,	NULL
suggesting	NULL
that	NULL
CD30	NULL
signaling	NULL
inhibits	NULL
the	NULL
CD4O0-mediated	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
Cy3	NULL
promoter	NULL
in	NULL
a	NULL
fashion	NULL
that	NULL
is	NULL
independent	NULL
of	NULL
B	NULL
cell-derived	NULL
cytokines	NULL
.	NULL

CD30	NULL
Engagement	NULL
Hampers	NULL
CD40-Mediated	NULL
Binding	NULL
of	NULL
p50/p65	NULL
,	NULL
p50/c-Rel	NULL
,	NULL
and	NULL
p50/p50	NULL
NF-xB	NULL
Complexes	NULL
to	NULL
the	NULL
CD40	NULL
Responsive	NULL
Element	NULL
of	NULL
the	NULL
Human	NULL
Cy3	NULL
Germline	NULL
Gene	NULL
Promoter	NULL
To	NULL
verify	NULL
whether	NULL
CD30	NULL
coengagement	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
decreased	NULL
binding	NULL
of	NULL
NF-xB	NULL
to	NULL
the	NULL
ECS-Iy3	NULL
CD4ORE	NULL
,	NULL
CL-O01	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
medium	NULL
only	NULL
or	NULL
in	NULL
medium	NULL
containing	NULL
htCD40L	NULL
(	NULL
0.5	NULL
ug/ml	NULL
!	NULL
)	NULL

in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
control	NULL
MOPC-21	NULL
MAb	NULL
or	NULL
anti-CD30	NULL
immobilized	NULL
MAbs	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
.	NULL

Parallel	NULL
experiments	NULL
were	NULL
performed	NULL
using	NULL
100	NULL
ug/ml	NULL
of	NULL
cycloheximide	NULL
(	NULL
CHX	NULL
)	NULL
as	NULL
inhibitor	NULL
of	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
.	NULL

Nuclear	NULL
proteins	NULL
were	NULL
extracted	NULL
after	NULL
6	NULL
hr	NULL
of	NULL
culture	NULL
,	NULL
incubated	NULL
(	NULL
3	NULL
ug	NULL
)	NULL
with	NULL
a	NULL
radiolabeled	NULL
DNA	NULL
probe	NULL
spanning	NULL
the	NULL
ECS-Iy3	NULL
xBI1	NULL
site	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
,	NULL
and	NULL
then	NULL
fractioned	NULL
through	NULL
a	NULL
6	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

Nuclear	NULL
proteins	NULL
from	NULL
CL-O01	NULL
cells	NULL
cultured	NULL
with	NULL
control	NULL
MOPC21	NULL
MAb	NULL
displayed	NULL
a	NULL
weak	NULL
DNA	NULL
binding	NULL
activity	NULL
represented	NULL
by	NULL
two	NULL
shifted	NULL
bands	NULL
with	NULL
slower	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
complex	NULL
A	NULL
)	NULL
and	NULL
faster	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
complex	NULL
B	NULL
)	NULL
mobility	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
both	NULL
complexes	NULL
was	NULL
slightly	NULL
increased	NULL
by	NULL
anti-CD30	NULL
MAb	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
,	NULL
while	NULL
it	NULL
was	NULL
dramatically	NULL
enhanced	NULL
by	NULL
htCD40L	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

CD4OL	NULL
induced	NULL
also	NULL
a	NULL
third	NULL
complex	NULL
with	NULL
the	NULL
fastest	NULL
mobility	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
complex	NULL
C	NULL
)	NULL
.	NULL

Shifted	NULL
bands	NULL
were	NULL
specific	NULL
,	NULL
as	NULL
they	NULL
were	NULL
cleared	NULL
by	NULL
the	NULL
preincubation	NULL
of	NULL
CD4O0L-induced	NULL
nuclear	NULL
proteins	NULL
with	NULL
an	NULL
excess	NULL
of	NULL
unlabeled	NULL
wild	NULL
type	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
competitor	NULL
1	NULL
,	NULL
lane	NULL
11	NULL
)	NULL
,	NULL
but	NULL
not	NULL
mutated	NULL
,	NULL
xB1	NULL
probe	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
competitor	NULL
2	NULL
,	NULL
lane	NULL
12	NULL
)	NULL
.	NULL

The	NULL
identity	NULL
of	NULL
complexes	NULL
A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
C	NULL
to	NULL
NF-xB/Rel	NULL
family	NULL
members	NULL
was	NULL
demonstrated	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
unlabeled	NULL
oligonucleotides	NULL
containing	NULL
a	NULL
palindromic	NULL
NF-xB	NULL
binding	NULL
sequence	NULL
from	NULL
the	NULL
Ig	NULL
x	NULL
promoter	NULL
to	NULL
compete	NULL
with	NULL
the	NULL
labeled	NULL
xB1	NULL
probe	NULL
for	NULL
binding	NULL
to	NULL
CD4O0L-induced	NULL
nuclear	NULL
proteins	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
competitor	NULL
3	NULL
,	NULL
lane	NULL
13	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
composition	NULL
of	NULL
complexes	NULL
A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
C	NULL
,	NULL
nuclear	NULL
proteins	NULL
from	NULL
htCD40L-induced	NULL
cells	NULL
were	NULL
preincubated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
a	NULL
control	NULL
Ab	NULL
with	NULL
irrelevant	NULL
binding	NULL
activity	NULL
or	NULL
with	NULL
Abs	NULL
to	NULL
human	NULL
p50	NULL
,	NULL
p52	NULL
,	NULL
p65	NULL
(	NULL
Rel	NULL
A	NULL
)	NULL
,	NULL
c-Rel	NULL
(	NULL
Rel	NULL
)	NULL
,	NULL
or	NULL
Rel	NULL
B	NULL
proteins	NULL
.	NULL

Anti-p50	NULL
,	NULL
anti-p65	NULL
,	NULL
and	NULL
anti-c-Rel	NULL
Abs	NULL
decreased	NULL
B1	NULL
binding	NULL
by	NULL
complexes	NULL
A	NULL
,	NULL
B	NULL
and	NULL
C	NULL
,	NULL
complex	NULL
A	NULL
,	NULL
and	NULL
complex	NULL
B	NULL
,	NULL
respectively	NULL
,	NULL
whereas	NULL
control	NULL
anti-thyreoglobulin	NULL
,	NULL
anti-p52	NULL
,	NULL
and	NULL
anti-Rel	NULL
B	NULL
Abs	NULL
did	NULL
not	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
lanes	NULL
14-19	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
complexes	NULL
A	NULL
and	NULL
B	NULL
corresponded	NULL
to	NULL
p50/p65	NULL
and	NULL
p50/c-Rel	NULL
heterodimers	NULL
,	NULL
respectively	NULL
,	NULL
and	NULL
complex	NULL
C	NULL
to	NULL
p50/p50	NULL
homodimers	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
anti-CD30	NULL
MAb	NULL
greatly	NULL
decreased	NULL
the	NULL
B1	NULL
binding	NULL
by	NULL
p50/p65	NULL
,	NULL
p50/c-Rel	NULL
,	NULL
and	NULL
p50/p50	NULL
complexes	NULL
regardless	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
CHX	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
compare	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
with	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
this	NULL
inhibition	NULL
was	NULL
confirmed	NULL
by	NULL
the	NULL
inability	NULL
of	NULL
an	NULL
immobilized	NULL
MAb	NULL
to	NULL
CD27	NULL
,	NULL
another	NULL
TNFR	NULL
superfamily	NULL
member	NULL
expressed	NULL
by	NULL
activated	NULL
normal	NULL
B	NULL
cells	NULL
and	NULL
CL-O1	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
to	NULL
inhibit	NULL
the	NULL
CD4O0L-induced	NULL
binding	NULL
(	NULL
Figure	NULL
6B	NULL
,	NULL
lane	NULL
10	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
CD30-dependent	NULL
inhibition	NULL
of	NULL
binding	NULL
to	NULL
the	NULL
Cy3	NULL
CD4O0RE	NULL
DNA	NULL
was	NULL
achieved	NULL
using	NULL
nuclear	NULL
proteins	NULL
from	NULL
freshly	NULL
isolated	NULL
normal	NULL
B	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
CD30	NULL
signaling	NULL
inhibits	NULL
the	NULL
CD4O0-mediated	NULL
binding	NULL
of	NULL
p50/p65	NULL
,	NULL
p50/c-Rel	NULL
,	NULL
and	NULL
p50/p50	NULL
NF-xB	NULL
complexes	NULL
to	NULL
the	NULL
CD4O0RE	NULL
of	NULL
the	NULL
human	NULL
Cy3	NULL
gene	NULL
promoter	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
7	NULL
Discussion	NULL
These	NULL
studies	NULL
show	NULL
that	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
CD30	NULL
effectively	NULL
down-regulates	NULL
Ig	NULL
class	NULL
switching	NULL
to	NULL
all	NULL
downstream	NULL
isotypes	NULL
by	NULL
inhibiting	NULL
targeted	NULL
DNA	NULL
recombination	NULL
to	NULL
Cy	NULL
,	NULL
Ca	NULL
,	NULL
,	NULL
and	NULL
Cs	NULL
through	NULL
interference	NULL
with	NULL
the	NULL
CD40-mediated	NULL
NF-xB-dependent	NULL
Cp	NULL
germline	NULL
gene	NULL
transcription	NULL
.	NULL

They	NULL
also	NULL
show	NULL
that	NULL
CD30	NULL
is	NULL
induced	NULL
in	NULL
naive	NULL
B	NULL
cells	NULL
by	NULL
engagement	NULL
of	NULL
CD40	NULL
by	NULL
CD4O0L	NULL
,	NULL
and	NULL
this	NULL
induction	NULL
is	NULL
hampered	NULL
by	NULL
BCR	NULL
engagement	NULL
and	NULL
,	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
,	NULL
exposure	NULL
to	NULL
IL-6	NULL
or	NULL
IL-12	NULL
,	NULL
in	NULL
a	NULL
fashion	NULL
that	NULL
is	NULL
consistent	NULL
with	NULL
a	NULL
critical	NULL
role	NULL
of	NULL
CD30	NULL
in	NULL
regulating	NULL
the	NULL
CD4O0-dependent	NULL
GC	NULL
B	NULL
cell	NULL
differentiation	NULL
.	NULL

Effective	NULL
T	NULL
and	NULL
B	NULL
lymphocyte	NULL
responses	NULL
involve	NULL
the	NULL
clonal	NULL
expansion	NULL
of	NULL
Ag-specific	NULL
cells	NULL
and	NULL
their	NULL
differentiation	NULL
into	NULL
effector	NULL
cells	NULL
.	NULL

This	NULL
critical	NULL
phase	NULL
of	NULL
expansion/	NULL
differentiation	NULL
is	NULL
driven	NULL
by	NULL
signals	NULL
delivered	NULL
by	NULL
the	NULL
receptor	NULL
for	NULL
Ag	NULL
,	NULL
costimulatory	NULL
molecules	NULL
,	NULL
and	NULL
cytokine	NULL
receptors	NULL
,	NULL
and	NULL
it	NULL
is	NULL
finely	NULL
tuned	NULL
by	NULL
the	NULL
simultaneous	NULL
activation	NULL
of	NULL
inhibitory	NULL
signaling	NULL
pathways	NULL
,	NULL
which	NULL
likely	NULL
play	NULL
a	NULL
major	NULL
role	NULL
in	NULL
the	NULL
self-limitation	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

In	NULL
the	NULL
B	NULL
cell	NULL
compartment	NULL
,	NULL
CD5	NULL
and	NULL
CD22	NULL
coreceptors	NULL
as	NULL
well	NULL
as	NULL
the	NULL
FeyRIIb	NULL
molecule	NULL
negatively	NULL
regulate	NULL
BCR-induced	NULL
B	NULL
cell	NULL
responses	NULL
(	NULL
O'Rourke	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Since	NULL
BCR	NULL
engagement	NULL
by	NULL
Ag	NULL
provides	NULL
a	NULL
major	NULL
signal	NULL
for	NULL
B	NULL
cell	NULL
proliferation	NULL
,	NULL
the	NULL
negative	NULL
modulation	NULL
of	NULL
BCR-mediated	NULL
signals	NULL
by	NULL
the	NULL
above	NULL
coreceptors	NULL
may	NULL
be	NULL
critical	NULL
to	NULL
limit	NULL
the	NULL
clonal	NULL
expansion	NULL
of	NULL
Ag-stimulated	NULL
B	NULL
cells	NULL
.	NULL

Signals	NULL
delivered	NULL
by	NULL
cytokine	NULL
receptors	NULL
may	NULL
also	NULL
be	NULL
tuned	NULL
by	NULL
inhibitory	NULL
pathways	NULL
.	NULL

Recently	NULL
,	NULL
cytokine-inducible	NULL
inhibitors	NULL
of	NULL
signaling	NULL
,	NULL
such	NULL
as	NULL
Janus	NULL
kinase	NULL
(	NULL
Jak	NULL
)	NULL
-binding	NULL
proteins	NULL
,	NULL
have	NULL
been	NULL
found	NULL
to	NULL
down-regulate	NULL
signals	NULL
emanating	NULL
from	NULL
Jak-STAT	NULL
(	NULL
signal	NULL
transducer	NULL
and	NULL
activator	NULL
of	NULL
transcription	NULL
)	NULL
-coupled	NULL
cytokine	NULL
receptors	NULL
,	NULL
including	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
IL-6	NULL
receptors	NULL
(	NULL
Endo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Naka	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

While	NULL
BCR	NULL
engagement	NULL
by	NULL
Ag	NULL
is	NULL
crucial	NULL
to	NULL
trigger	NULL
Ig	NULL
somatic	NULL
hypermutation	NULL
,	NULL
CD40	NULL
is	NULL
the	NULL
major	NULL
driver	NULL
of	NULL
B	NULL
cell	NULL
proliferation	NULL
and	NULL
differentiation	NULL
in	NULL
the	NULL
GC	NULL
(	NULL
Van	NULL
Kooten	NULL
and	NULL
Banchereau	NULL
,	NULL
1996	NULL
;	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998b	NULL
)	NULL
.	NULL

Because	NULL
of	NULL
the	NULL
critical	NULL
role	NULL
of	NULL
CD4Q	NULL
in	NULL
the	NULL
GC	NULL
B	NULL
cell	NULL
development	NULL
,	NULL
it	NULL
is	NULL
conceivable	NULL
that	NULL
CD4O0-mediated	NULL
B	NULL
cell	NULL
responses	NULL
,	NULL
including	NULL
proliferation	NULL
and	NULL
differentiation	NULL
,	NULL
are	NULL
finely	NULL
tuned	NULL
by	NULL
the	NULL
activation	NULL
of	NULL
signaling	NULL
pathways	NULL
that	NULL
negatively	NULL
regulate	NULL
CD4Q	NULL
signaling	NULL
.	NULL

This	NULL
negative	NULL
feedback	NULL
would	NULL
be	NULL
particularly	NULL
important	NULL
to	NULL
limit	NULL
the	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
those	NULL
CD4O-activated	NULL
B	NULL
cells	NULL
that	NULL
are	NULL
not	NULL
positively	NULL
selected	NULL
by	NULL
the	NULL
Ag	NULL
.	NULL

B	NULL
cells	NULL
express	NULL
CD95	NULL
upon	NULL
CD40	NULL
engagement	NULL
by	NULL
CD4O0L	NULL
,	NULL
and	NULL
CD95	NULL
engagement	NULL
by	NULL
CD95L	NULL
would	NULL
prevent	NULL
the	NULL
CD4O0-mediated	NULL
proliferation	NULL
of	NULL
non-Ag-selected	NULL
B	NULL
cells	NULL
by	NULL
inducing	NULL
their	NULL
apoptosis	NULL
(	NULL
Schattner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
non-Ag-selected	NULL
B	NULL
cells	NULL
express	NULL
CD30	NULL
upon	NULL
CD40	NULL
engagement	NULL
by	NULL
CD4OL	NULL
and	NULL
that	NULL
CD30	NULL
engagement	NULL
by	NULL
CD30L	NULL
counteracts	NULL
CD4O0L	NULL
:	NULL
CD4O0-induced	NULL
B	NULL
cell	NULL
differentiation	NULL
,	NULL
including	NULL
Ig	NULL
class	NULL
switching	NULL
.	NULL

In	NULL
CL-O1	NULL
B	NULL
cells	NULL
,	NULL
CD40	NULL
engagement	NULL
by	NULL
CD4OL	NULL
effectively	NULL
induces	NULL
Iu-Cy	NULL
,	NULL
Iy1-Cy1	NULL
,	NULL
Iy2-Cy2	NULL
,	NULL
1y3-Cy3	NULL
,	NULL
and	NULL
Ia	NULL
1-Cal	NULL
transcription	NULL
,	NULL
endogenous	NULL
TGFB	NULL
production	NULL
,	NULL
and	NULL
eventually	NULL
switch	NULL
DNA	NULL
recombination	NULL
to	NULL
Cy1	NULL
and	NULL
Cal	NULL
.	NULL

The	NULL
addition	NULL
of	NULL
IL-4	NULL
extends	NULL
germline	NULL
transcription	NULL
to	NULL
I1y4-Cy4	NULL
,	NULL
Ia2-Ca2	NULL
,	NULL
and	NULL
Is-Cs	NULL
and	NULL
triggers	NULL
switch	NULL
DNA	NULL
recombination	NULL
to	NULL
all	NULL
remaining	NULL
downstream	NULL
isotypes	NULL
,	NULL
as	NULL
indicated	NULL
by	NULL
the	NULL
detection	NULL
of	NULL
the	NULL
corresponding	NULL
productive	NULL
Ig	NULL
transcripts	NULL
and	NULL
switch	NULL
circles	NULL
(	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

The	NULL
present	NULL
experiments	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
8	NULL
show	NULL
that	NULL
CD30	NULL
signaling	NULL
inhibits	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
all	NULL
of	NULL
the	NULL
above	NULL
Cy	NULL
genes	NULL
as	NULL
well	NULL
as	NULL
their	NULL
targeted	NULL
recombination	NULL
without	NULL
interfering	NULL
with	NULL
the	NULL
expression	NULL
of	NULL
surface	NULL
CD40	NULL
.	NULL

They	NULL
also	NULL
show	NULL
that	NULL
CD30	NULL
coengagement	NULL
does	NULL
not	NULL
interfere	NULL
with	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
VgDJy-Cu	NULL
transcript	NULL
,	NULL
nor	NULL
does	NULL
it	NULL
affect	NULL
other	NULL
CD4O0-mediated	NULL
B	NULL
cell	NULL
responses	NULL
including	NULL
proliferation	NULL
,	NULL
enhancement	NULL
of	NULL
Ig	NULL
M	NULL
secretion	NULL
,	NULL
or	NULL
CD23	NULL
,	NULL
CD54	NULL
,	NULL
CD80	NULL
,	NULL
CD86	NULL
,	NULL
and	NULL
CD95	NULL
up-regulation	NULL
(	NULL
Ranheim	NULL
and	NULL
Kipps	NULL
,	NULL
1993	NULL
;	NULL
Schattner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Hanissian	NULL
and	NULL
Geha	NULL
,	NULL
1997	NULL
)	NULL
.	NULL

These	NULL
CD40-dependent	NULL
processes	NULL
would	NULL
entail	NULL
the	NULL
induction	NULL
of	NULL
a	NULL
vast	NULL
array	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

It	NULL
is	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
CD30	NULL
preferentially	NULL
interferes	NULL
with	NULL
those	NULL
CD40-emanating	NULL
signaling	NULL
pathways	NULL
that	NULL
are	NULL
related	NULL
to	NULL
Ig	NULL
class	NULL
switching	NULL
.	NULL

The	NULL
signaling	NULL
pathway	NULL
by	NULL
which	NULL
CD30	NULL
inhibits	NULL
Ig	NULL
class	NULL
switching	NULL
would	NULL
ultimately	NULL
impinge	NULL
on	NULL
the	NULL
cis	NULL
regulatory	NULL
elements	NULL
that	NULL
lie	NULL
upstream	NULL
of	NULL
the	NULL
human	NULL
Cy	NULL
regions	NULL
.	NULL

As	NULL
we	NULL
have	NULL
shown	NULL
(	NULL
Schaffer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
,	NULL
engagement	NULL
of	NULL
CD40	NULL
by	NULL
CD4OL	NULL
induces	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
Cy3	NULL
promoter	NULL
,	NULL
and	NULL
this	NULL
activation	NULL
is	NULL
boosted	NULL
by	NULL
IL-4	NULL
.	NULL

CD30	NULL
coengagement	NULL
reduces	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
Cy3	NULL
promoter	NULL
induced	NULL
by	NULL
CD4OL	NULL
alone	NULL
and	NULL
CD4O0L	NULL
and	NULL
IL-4	NULL
,	NULL
but	NULL
not	NULL
IL-4	NULL
alone	NULL
,	NULL
suggesting	NULL
that	NULL
CD30	NULL
interferes	NULL
with	NULL
the	NULL
CD40	NULL
but	NULL
not	NULL
the	NULL
IL-4	NULL
signaling	NULL
pathway	NULL
.	NULL

The	NULL
failure	NULL
of	NULL
neutralizing	NULL
Abs	NULL
to	NULL
IL-6	NULL
,	NULL
IL-10	NULL
,	NULL
or	NULL
IFNy	NULL
to	NULL
affect	NULL
the	NULL
CD30-mediated	NULL
inhibition	NULL
of	NULL
the	NULL
CD4O0-driven	NULL
Cy3	NULL
germline	NULL
gene	NULL
transcriptional	NULL
activation	NULL
virtually	NULL
excludes	NULL
the	NULL
possibility	NULL
that	NULL
this	NULL
inhibition	NULL
is	NULL
mediated	NULL
by	NULL
endogenous	NULL
IL-6	NULL
,	NULL
IL-10	NULL
,	NULL
TGF	NULL
$	NULL
B	NULL
,	NULL
or	NULL
IFNy	NULL
(	NULL
Gruss	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Yoshimoto	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
;	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
;	NULL
Zan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998a	NULL
)	NULL
,	NULL
which	NULL
are	NULL
all	NULL
known	NULL
to	NULL
modulate	NULL
Cy	NULL
gene	NULL
transcriptional	NULL
activation	NULL
and/or	NULL
B	NULL
cell	NULL
proliferation	NULL
(	NULL
Stavnezer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Morse	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Rather	NULL
,	NULL
our	NULL
experiments	NULL
show	NULL
that	NULL
CD30	NULL
triggering	NULL
inhibits	NULL
the	NULL
CD4O0L-induced	NULL
germline	NULL
transcription	NULL
of	NULL
Cy3	NULL
and	NULL
,	NULL
possibly	NULL
,	NULL
other	NULL
Cp	NULL
genes	NULL
by	NULL
hampering	NULL
the	NULL
activation	NULL
of	NULL
transcription	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
upstream	NULL
cis	NULL
regulatory	NULL
sequences	NULL
.	NULL

CD40	NULL
cross-linking	NULL
induces	NULL
the	NULL
activation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
different	NULL
NF-xB/Rel	NULL
family	NULL
members	NULL
,	NULL
including	NULL
p50	NULL
,	NULL
p65	NULL
(	NULL
Rel	NULL
A	NULL
)	NULL
,	NULL
and	NULL
c-Rel	NULL
,	NULL
which	NULL
are	NULL
thought	NULL
to	NULL
regulate	NULL
the	NULL
CD40-dependent	NULL
germline	NULL
transcription	NULL
of	NULL
a	NULL
given	NULL
Cy	NULL
gene	NULL
by	NULL
binding	NULL
critical	NULL
DNA	NULL
elements	NULL
located	NULL
within	NULL
the	NULL
corresponding	NULL
upstream	NULL
promoter	NULL
(	NULL
Stavnezer	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
the	NULL
CD40-dependent	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
Cy3	NULL
germline	NULL
gene	NULL
promoter	NULL
relies	NULL
upon	NULL
the	NULL
presence	NULL
of	NULL
two	NULL
tandemly	NULL
arrayed	NULL
xB	NULL
sites	NULL
,	NULL
which	NULL
bind	NULL
p50/p65	NULL
and	NULL
p50/c-Rel	NULL
heterodimers	NULL
as	NULL
well	NULL
as	NULL
p50/p50	NULL
homodimers	NULL
.	NULL

By	NULL
showing	NULL
that	NULL
CD30	NULL
significantly	NULL
decreases	NULL
CD4O0-induced	NULL
binding	NULL
of	NULL
p50/p65	NULL
,	NULL
p50/c-Rel	NULL
,	NULL
and	NULL
p50/p350	NULL
NF-	NULL
«	NULL
B	NULL
complexes	NULL
to	NULL
this	NULL
CD4O0RE	NULL
,	NULL
our	NULL
findings	NULL
indicate	NULL
that	NULL
CD30	NULL
signaling	NULL
specifically	NULL
interferes	NULL
with	NULL
the	NULL
CD4O0-mediated	NULL
NF-xB	NULL
dependent	NULL
transcriptional	NULL
activation	NULL
of	NULL
human	NULL
Ig	NULL
Cy	NULL
genes	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
this	NULL
inhibition	NULL
is	NULL
suggested	NULL
by	NULL
our	NULL
demonstration	NULL
that	NULL
cross-linking	NULL
of	NULL
CD27	NULL
,	NULL
another	NULL
member	NULL
of	NULL
the	NULL
TNFR	NULL
superfamily	NULL
expressed	NULL
by	NULL
activated	NULL
B	NULL
cells	NULL
,	NULL
including	NULL
CL-O1	NULL
cells	NULL
,	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
CD4O0L-induced	NULL
binding	NULL
to	NULL
the	NULL
B1	NULL
sequence	NULL
.	NULL

CD40	NULL
cross-linking	NULL
activates	NULL
NF-xB/Re	NULL
!	NULL

family	NULL
members	NULL
by	NULL
inducing	NULL
the	NULL
recruitment	NULL
of	NULL
TNFR-associated	NULL
proteins	NULL
(	NULL
TRAFs	NULL
)	NULL
,	NULL
including	NULL
TRAF-2	NULL
,	NULL
to	NULL
the	NULL
CD40	NULL
cytoplasmic	NULL
domain	NULL
(	NULL
Rothe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Kehry	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

Accumulating	NULL
evidence	NULL
suggests	NULL
that	NULL
CD4O0-mediated	NULL
B	NULL
cell	NULL
responses	NULL
can	NULL
be	NULL
altered	NULL
by	NULL
signals	NULL
able	NULL
to	NULL
quantitatively	NULL
and/or	NULL
qualitatively	NULL
modify	NULL
the	NULL
TRAF	NULL
composition	NULL
of	NULL
the	NULL
CD40	NULL
receptor	NULL
complex	NULL
(	NULL
Kuhné	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Putative	NULL
inhibitors	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
9	NULL
of	NULL
the	NULL
TRAF-2-mediated	NULL
NF-KB	NULL
activation	NULL
,	NULL
including	NULL
I-TRAF/TANK	NULL
,	NULL
A20	NULL
,	NULL
TRAF-3	NULL
,	NULL
and	NULL
TRIP	NULL
,	NULL
a	NULL
TRAF-2	NULL
interacting	NULL
protein	NULL
that	NULL
associates	NULL
with	NULL
the	NULL
CD30	NULL
cytoplasmic	NULL
domain	NULL
,	NULL
might	NULL
be	NULL
associated	NULL
with	NULL
the	NULL
negative	NULL
regulation	NULL
of	NULL
the	NULL
CD4O0	NULL
:	NULL
TRAF-2	NULL
signaling	NULL
pathway	NULL
(	NULL
Rothe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
,	NULL
1996	NULL
;	NULL
Song	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

Our	NULL
experiments	NULL
suggest	NULL
that	NULL
the	NULL
CD30-dependent	NULL
inhibition	NULL
of	NULL
CD4O0L	NULL
:	NULL
CD4O0-induced	NULL
Ig	NULL
class	NULL
switching	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
does	NULL
not	NULL
rely	NULL
on	NULL
CD30-inducible	NULL
genes	NULL
,	NULL
but	NULL
rather	NULL
on	NULL
the	NULL
modulation	NULL
of	NULL
preformed	NULL
signal	NULL
transducers	NULL
.	NULL

Triggering	NULL
of	NULL
surface	NULL
CD30	NULL
may	NULL
induce	NULL
recruitment	NULL
of	NULL
TRAF-2	NULL
to	NULL
the	NULL
CD30	NULL
cytoplasmic	NULL
domain	NULL
,	NULL
thereby	NULL
subtracting	NULL
TRAF-2	NULL
from	NULL
its	NULL
association	NULL
with	NULL
the	NULL
CD40	NULL
cytoplasmic	NULL
domain	NULL
(	NULL
Ansieau	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
rapid	NULL
protease-mediated	NULL
degradation	NULL
of	NULL
CD30-bound	NULL
TRAF-2	NULL
might	NULL
induce	NULL
depletion	NULL
of	NULL
cytosolic	NULL
TRAF-2	NULL
and	NULL
further	NULL
desensitization	NULL
of	NULL
the	NULL
CD4O0	NULL
receptor	NULL
complex	NULL
(	NULL
Duckett	NULL
and	NULL
Thompson	NULL
,	NULL
1997	NULL
)	NULL
.	NULL

An	NULL
alternative	NULL
but	NULL
not	NULL
mutually	NULL
exclusive	NULL
possibility	NULL
is	NULL
that	NULL
CD30	NULL
cross-linking	NULL
may	NULL
alter	NULL
the	NULL
balance	NULL
between	NULL
TRAF-2	NULL
and	NULL
inhibitors	NULL
of	NULL
the	NULL
TRAF-2-dependent	NULL
NF-KB	NULL
activation	NULL
such	NULL
as	NULL
I-TRAF	NULL
,	NULL
A20	NULL
,	NULL
and	NULL
TRAF-3	NULL
.	NULL

Finally	NULL
,	NULL
simultaneous	NULL
CD4O	NULL
and	NULL
CD30	NULL
multimerization	NULL
might	NULL
bring	NULL
the	NULL
corresponding	NULL
cognate	NULL
signaling	NULL
complexes	NULL
in	NULL
such	NULL
close	NULL
proximity	NULL
that	NULL
CD30-bound	NULL
TRIP	NULL
would	NULL
associate	NULL
and	NULL
inhibit	NULL
CD40-bound	NULL
TRAF-2	NULL
.	NULL

The	NULL
CD30-induced	NULL
redistribution	NULL
,	NULL
decreased	NULL
availability	NULL
,	NULL
and/or	NULL
inactivation	NULL
of	NULL
TRAF-2	NULL
might	NULL
impair	NULL
the	NULL
CD40-mediated	NULL
TRAF-2-dependent	NULL
activation	NULL
of	NULL
NF-xB-inducing	NULL
kinase	NULL
and	NULL
IB	NULL
kinase	NULL
,	NULL
two	NULL
compounds	NULL
that	NULL
mediate	NULL
NF-xB	NULL
activation	NULL
by	NULL
inducing	NULL
IxB	NULL
phosphorylation	NULL
(	NULL
Régnier	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

These	NULL
membrane-proximal	NULL
and	NULL
other	NULL
more	NULL
distal	NULL
models	NULL
of	NULL
CD30-mediated	NULL
interference	NULL
on	NULL
CD40	NULL
signals	NULL
are	NULL
currently	NULL
under	NULL
study	NULL
.	NULL

The	NULL
different	NULL
outcome	NULL
of	NULL
CD40-mediated	NULL
signals	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CD30	NULL
engagement	NULL
by	NULL
CD30L	NULL
suggests	NULL
a	NULL
key	NULL
regulatory	NULL
role	NULL
of	NULL
CD30	NULL
in	NULL
the	NULL
homeostasis	NULL
of	NULL
GC	NULL
B	NULL
cells	NULL
and	NULL
is	NULL
reminescent	NULL
of	NULL
the	NULL
ability	NULL
of	NULL
other	NULL
TNF	NULL
receptor	NULL
:	NULL
ligand	NULL
pairs	NULL
such	NULL
as	NULL
€CD27	NULL
:	NULL
CD70	NULL
and	NULL
OX40	NULL
:	NULL
OXAOL	NULL
to	NULL
modulate	NULL
and	NULL
complement	NULL
CD4O0L	NULL
:	NULL
CD4O0-mediated	NULL
B	NULL
cell	NULL
responses	NULL
(	NULL
Stuber	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
;	NULL
Jacquot	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

We	NULL
have	NULL
found	NULL
that	NULL
naive	NULL
B	NULL
cells	NULL
express	NULL
surface	NULL
CD30	NULL
as	NULL
early	NULL
as	NULL
24	NULL
hr	NULL
after	NULL
CD40	NULL
engagement	NULL
by	NULL
CD4O0L	NULL
,	NULL
that	NULL
is	NULL
,	NULL
within	NULL
the	NULL
same	NULL
time	NULL
frame	NULL
required	NULL
by	NULL
activated	NULL
T	NULL
cells	NULL
to	NULL
express	NULL
surface	NULL
CD3O0L	NULL
(	NULL
Smith	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

CD4OL	NULL
is	NULL
expressed	NULL
by	NULL
CD4*	NULL
T	NULL
cells	NULL
as	NULL
early	NULL
as	NULL
4	NULL
hr	NULL
after	NULL
appropriate	NULL
stimulation	NULL
(	NULL
Van	NULL
Kooten	NULL
and	NULL
Banchereau	NULL
,	NULL
1996	NULL
)	NULL
,	NULL
and	NULL
CD40	NULL
engagement	NULL
by	NULL
CD4OL	NULL
initiates	NULL
germline	NULL
transcription	NULL
of	NULL
Cy	NULL
genes	NULL
in	NULL
B	NULL
cells	NULL
within	NULL
a	NULL
few	NULL
hours	NULL
(	NULL
Stavnezer	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

The	NULL
differential	NULL
timing	NULL
of	NULL
CD30	NULL
,	NULL
CD30L	NULL
,	NULL
and	NULL
CD4OL	NULL
expression	NULL
further	NULL
supports	NULL
our	NULL
contention	NULL
that	NULL
CD30	NULL
is	NULL
critical	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
CD4O0-driven	NULL
Ig	NULL
class	NULL
switching	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

Despite	NULL
the	NULL
crucial	NULL
role	NULL
played	NULL
by	NULL
CD4O0L	NULL
:	NULL
CD4O0-mediated	NULL
T-B	NULL
cell	NULL
contact	NULL
in	NULL
the	NULL
development	NULL
of	NULL
normal	NULL
B	NULL
cell	NULL
responses	NULL
(	NULL
Aruffo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
only	NULL
rare	NULL
GC	NULL
B	NULL
cells	NULL
express	NULL
surface	NULL
CD30	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
generation	NULL
of	NULL
these	NULL
elements	NULL
is	NULL
tightly	NULL
regulated	NULL
in	NULL
vivo	NULL
.	NULL

By	NULL
showing	NULL
that	NULL
BCR	NULL
engagement	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
IL-12	NULL
prevent	NULL
the	NULL
CD4O0L-induced	NULL
expression	NULL
of	NULL
CD30	NULL
but	NULL
not	NULL
that	NULL
of	NULL
GC	NULL
markers	NULL
,	NULL
our	NULL
findings	NULL
suggest	NULL
that	NULL
human	NULL
B	NULL
cells	NULL
express	NULL
this	NULL
TNFR-like	NULL
molecule	NULL
upon	NULL
interaction	NULL
with	NULL
CD4*CD40L*	NULL
T	NULL
cells	NULL
only	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Ag-presenting	NULL
cells	NULL
such	NULL
as	NULL
dendritic	NULL
cells	NULL
(	NULL
Figure	NULL
7	NULL
)	NULL
.	NULL

These	NULL
cells	NULL
would	NULL
antagonize	NULL
the	NULL
CD30	NULL
expression	NULL
by	NULL
B	NULL
cells	NULL
in	NULL
two	NULL
ways	NULL
:	NULL
by	NULL
engaging	NULL
the	NULL
BCR	NULL
through	NULL
Ag	NULL
complexes	NULL
and	NULL
by	NULL
secreting	NULL
IL-6	NULL
and	NULL
IL-12	NULL
in	NULL
response	NULL
to	NULL
the	NULL
engagement	NULL
of	NULL
their	NULL
surface	NULL
CD40	NULL
by	NULL
T	NULL
cell	NULL
CD4OL	NULL
(	NULL
Grewal	NULL
and	NULL
Flawell	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

BCR	NULL
engagement	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
inhibit	NULL
the	NULL
CD4O0-mediated	NULL
up-regulation	NULL
of	NULL
another	NULL
member	NULL
of	NULL
the	NULL
TNFR	NULL
family	NULL
,	NULL
CD95	NULL
(	NULL
Choe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1996	NULL
;	NULL
Kuhné	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
.	NULL

The	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
10	NULL
transitory	NULL
expression	NULL
of	NULL
CD4O0L	NULL
by	NULL
T	NULL
cells	NULL
and/or	NULL
the	NULL
rapid	NULL
cleavage	NULL
of	NULL
CD30	NULL
through	NULL
disintegrin	NULL
metalloproteinases	NULL
released	NULL
by	NULL
CD4O-activated	NULL
dendritic	NULL
cells	NULL
(	NULL
Mueller	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1997	NULL
)	NULL
may	NULL
represent	NULL
two	NULL
additional	NULL
mechanisms	NULL
limiting	NULL
the	NULL
CD30	NULL
expression	NULL
by	NULL
B	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
our	NULL
findings	NULL
indicate	NULL
that	NULL
the	NULL
CD30	NULL
pathway	NULL
represents	NULL
a	NULL
negative	NULL
feedback	NULL
limiting	NULL
the	NULL
CD4O0-driven	NULL
progression	NULL
of	NULL
nonAg-selected	NULL
B	NULL
cells	NULL
into	NULL
isotype-switched	NULL
B	NULL
cells	NULL
.	NULL

Defects	NULL
involving	NULL
the	NULL
CD30	NULL
pathway	NULL
and/or	NULL
the	NULL
processes	NULL
leading	NULL
to	NULL
the	NULL
deletion	NULL
of	NULL
CD30*	NULL
B	NULL
cells	NULL
might	NULL
either	NULL
generate	NULL
autoreactive	NULL
B	NULL
clonotypes	NULL
secreting	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
or	NULL
IgE	NULL
with	NULL
pathogenic	NULL
potential	NULL
and/or	NULL
favor	NULL
the	NULL
neoplastic	NULL
transformation	NULL
of	NULL
CD30+*	NULL
B	NULL
cells	NULL
.	NULL

Experimental	NULL
Procedures	NULL
Cells	NULL
The	NULL
human	NULL
CL-O1	NULL
B	NULL
cell	NULL
line	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
healthy	NULL
subjects	NULL
and	NULL
depleted	NULL
of	NULL
T	NULL
cells	NULL
by	NULL
sheep	NULL
red	NULL
blood	NULL
cells	NULL
rosetting	NULL
.	NULL

T	NULL
cell-depleted	NULL
cells	NULL
were	NULL
first	NULL
reacted	NULL
with	NULL
a	NULL
mouse	NULL
MAb	NULL
to	NULL
human	NULL
IgD	NULL
(	NULL
Southern	NULL
Biotechnology	NULL
Associates	NULL
,	NULL
Birmingham	NULL
,	NULL
AL	NULL
)	NULL
,	NULL
and	NULL
then	NULL
with	NULL
magnetic	NULL
Microbeads	NULL
conjugated	NULL
with	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
,	NULL
Auburn	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

sIgD*	NULL
B	NULL
cells	NULL
were	NULL
segregated	NULL
using	NULL
a	NULL
magnetic	NULL
sorter	NULL
MACS	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
)	NULL
.	NULL

CD8*CD30L*	NULL
T	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
total	NULL
T	NULL
cells	NULL
after	NULL
depletion	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
with	NULL
CD4-coated	NULL
magnetic	NULL
beads	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
)	NULL
and	NULL
incubation	NULL
with	NULL
1:100	NULL
phytohemoagglutinin	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
and	NULL
100	NULL
U/ml	NULL
!	NULL

of	NULL
IL-2	NULL
(	NULL
Genzyme	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
for	NULL
2	NULL
days	NULL
.	NULL

For	NULL
T-B	NULL
cell	NULL
cocultures	NULL
,	NULL
CD30L*	NULL
T	NULL
cells	NULL
were	NULL
fixed	NULL
in	NULL
0.5	NULL
%	NULL
paraformaldehyde	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
.	NULL

The	NULL
inhibitory	NULL
activity	NULL
of	NULL
these	NULL
cells	NULL
on	NULL
Ig	NULL
class	NULL
switching	NULL
was	NULL
critically	NULL
CD30L-dependent	NULL
,	NULL
as	NULL
it	NULL
was	NULL
prevented	NULL
by	NULL
their	NULL
preincubation	NULL
with	NULL
10	NULL
ug/ml	NULL
of	NULL
human	NULL
CD30-1IgG1	NULL
Fc	NULL
chimeric	NULL
protein	NULL
(	NULL
Immunex	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
)	NULL
.	NULL

Culture	NULL
Conditions	NULL
B	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
heat-inactivated	NULL
FBS	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
100	NULL
U/mL	NULL
penicillin	NULL
,	NULL
100	NULL
ug/ml	NULL
!	NULL

streptomycin	NULL
,	NULL
and	NULL
2	NULL
%	NULL
HEPES	NULL
.	NULL

CL-01	NULL
cells	NULL
(	NULL
104	NULL
)	NULL
or	NULL
naive	NULL
B	NULL
cells	NULL
(	NULL
10°	NULL
)	NULL
were	NULL
seeded	NULL
in	NULL
96-well	NULL
microculture	NULL
plates	NULL
with	NULL
or	NULL
without	NULL
htCD40L	NULL
(	NULL
0.5	NULL
ug/ml	NULL
!	NULL
)	NULL

(	NULL
Immunex	NULL
)	NULL
at	NULL
the	NULL
final	NULL
volume	NULL
of	NULL
200	NULL
ul	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
used	NULL
at	NULL
2	NULL
x	NULL
104	NULL
or	NULL
2	NULL
x	NULL
10°/well	NULL
.	NULL

MOPC-21	NULL
(	NULL
Sigma	NULL
Chemicals	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
anti-CD30	NULL
(	NULL
Immunex	NULL
)	NULL
,	NULL
and	NULL
anti-CD27	NULL
(	NULL
Immunotech	NULL
,	NULL
Westbrook	NULL
,	NULL
ME	NULL
)	NULL
MAbs	NULL
were	NULL
coated	NULL
onto	NULL
polystyrene	NULL
plates	NULL
at	NULL
5	NULL
ug/ml	NULL
.	NULL

BCR	NULL
triggering	NULL
was	NULL
performed	NULL
using	NULL
2	NULL
ug/ml	NULL
of	NULL
anti-	NULL
and	NULL
anti-A	NULL
chain	NULL
MAbs	NULL
(	NULL
ICN	NULL
Pharmaceutical	NULL
,	NULL
Costa	NULL
Mesa	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Recombinant	NULL
human	NULL
IL-1	NULL
,	NULL
IL-2	NULL
,	NULL
IL-6	NULL
,	NULL
IL-7	NULL
,	NULL
IL-13	NULL
,	NULL
TGFPB1	NULL
,	NULL
TNFa	NULL
,	NULL
LTB	NULL
,	NULL
IFNy	NULL
(	NULL
Genzyme	NULL
Co.	NULL
)	NULL
,	NULL
IL-4	NULL
,	NULL
IL-10	NULL
(	NULL
Schering-Plough	NULL
)	NULL
,	NULL
and	NULL
IL-12	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
B.	NULL
Perussia	NULL
)	NULL
were	NULL
used	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10	NULL
ng/ml	NULL
,	NULL
200	NULL
U/ml	NULL
,	NULL
200	NULL
ng/ml	NULL
,	NULL
100	NULL
U/ml	NULL
,	NULL
5	NULL
ng/ml	NULL
,	NULL
0.5	NULL
ng/ml1	NULL
,	NULL
2.5	NULL
ng/ml	NULL
,	NULL
2.5	NULL
ng/ml	NULL
,	NULL
200	NULL
U/ml	NULL
,	NULL
100	NULL
U/ml	NULL
,	NULL
200	NULL
ng/ml	NULL
,	NULL
and	NULL
1	NULL
ng/ml	NULL
,	NULL
respectively	NULL
.	NULL

Neutralizing	NULL
Abs	NULL
to	NULL
human	NULL
IFNy	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
B.	NULL
Perussia	NULL
)	NULL
as	NULL
well	NULL
as	NULL
to	NULL
IL-6	NULL
,	NULL
IL-10	NULL
,	NULL
and	NULL
TGFB	NULL
(	NULL
Genzyme	NULL
)	NULL
were	NULL
used	NULL
at	NULL
1:500	NULL
and	NULL
30	NULL
ug/ml	NULL
,	NULL
respectively	NULL
.	NULL

Cycloheximide	NULL
(	NULL
Sigma	NULL
Chemicals	NULL
)	NULL
was	NULL
used	NULL
at	NULL
100	NULL
ug/ml	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
11	NULL
Fluorescence	NULL
Flow	NULL
Cytometry	NULL
Mouse	NULL
fluorescein	NULL
(	NULL
FITC	NULL
)	NULL
-	NULL
or	NULL
phycoerytrin	NULL
(	NULL
PE	NULL
)	NULL
-conjugated	NULL
Abs	NULL
to	NULL
the	NULL
following	NULL
human	NULL
Ags	NULL
were	NULL
used	NULL
:	NULL
CD40L	NULL
,	NULL
CD80	NULL
,	NULL
and	NULL
CD95	NULL
(	NULL
Ancell	NULL
,	NULL
Bayport	NULL
,	NULL
MN	NULL
)	NULL
;	NULL
CD54	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
;	NULL
CD30	NULL
and	NULL
CD71	NULL
(	NULL
Dako	NULL
,	NULL
Carpinteria	NULL
,	NULL
CA	NULL
)	NULL
;	NULL
CD40	NULL
and	NULL
CD86	NULL
(	NULL
PharMingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
;	NULL
CD3	NULL
,	NULL
CD4	NULL
,	NULL
CD38	NULL
,	NULL
and	NULL
CD19	NULL
(	NULL
Sigma	NULL
Chemicals	NULL
)	NULL
;	NULL
and	NULL
CD23	NULL
(	NULL
Coulter	NULL
,	NULL
Hialeh	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

Unconjugated	NULL
mouse	NULL
M81	NULL
MAb	NULL
to	NULL
human	NULL
CD3O0L	NULL
(	NULL
Immunex	NULL
)	NULL
was	NULL
labeled	NULL
with	NULL
FITC-conjugated	NULL
goat	NULL
Ab	NULL
to	NULL
mouse	NULL
Ig	NULL
(	NULL
PharMingen	NULL
)	NULL
.	NULL

Cells	NULL
(	NULL
104	NULL
)	NULL
were	NULL
acquired	NULL
using	NULL
a	NULL
FACScalibur	NULL
analyzer	NULL
and	NULL
data	NULL
were	NULL
processed	NULL
using	NULL
a	NULL
Macintosh	NULL
CELL-Quest	NULL
software	NULL
program	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Proliferation	NULL
Assays	NULL
B	NULL
cells	NULL
(	NULL
10°	NULL
)	NULL
were	NULL
seeded	NULL
in	NULL
96-well	NULL
U-shaped	NULL
microtiter	NULL
plates	NULL
under	NULL
different	NULL
conditions	NULL
and	NULL
pulsed	NULL
with	NULL
1	NULL
uCi	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
JTdR	NULL
at	NULL
day	NULL
5	NULL
of	NULL
culture	NULL
.	NULL

After	NULL
18	NULL
hr	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
for	NULL
the	NULL
measurement	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
JTdR	NULL
uptake	NULL
.	NULL

The	NULL
stimulation	NULL
index	NULL
was	NULL
calculated	NULL
according	NULL
to	NULL
the	NULL
formula	NULL
:	NULL
mean	NULL
of	NULL
cpm	NULL
of	NULL
triplicates	NULL
with	NULL
stimulus/mean	NULL
of	NULL
cpm	NULL
of	NULL
triplicates	NULL
without	NULL
stimulus	NULL
.	NULL

Amplification	NULL
of	NULL
CD30	NULL
,	NULL
Iy-CpH	NULL
,	NULL
and	NULL
VyDJp-C	NULL
»	NULL
Transcripts	NULL
RNA	NULL
was	NULL
isolated	NULL
using	NULL
the	NULL
RNeasy	NULL
Total	NULL
RNA	NULL
Kit	NULL
(	NULL
Qiagen	NULL
,	NULL
Chatsworth	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
and	NULL
equal	NULL
amounts	NULL
(	NULL
3	NULL
ug	NULL
)	NULL
were	NULL
reversed	NULL
transcribed	NULL
into	NULL
cDNA	NULL
using	NULL
the	NULL
SuperScript	NULL
reverse	NULL
transcriptase	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
and	NULL
an	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
1	NULL
;	NULL
_1g	NULL
primer	NULL
.	NULL

cDNA	NULL
was	NULL
measured	NULL
and	NULL
utilized	NULL
in	NULL
equal	NULL
amounts	NULL
as	NULL
template	NULL
to	NULL
PCR	NULL
amplify	NULL
(	NULL
20	NULL
cycles	NULL
)	NULL
In-Cy	NULL
and	NULL
VyDJy-Cy	NULL
transcripts	NULL
and	NULL
B-actin	NULL
(	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

To	NULL
amplify	NULL
CD30	NULL
cDNA	NULL
,	NULL
PCRs	NULL
were	NULL
performed	NULL
using	NULL
1U	NULL
of	NULL
Taq	NULL
polymerase	NULL
(	NULL
Perkin-Elmer	NULL
Cetus	NULL
Corp.	NULL
,	NULL
Norwalk	NULL
,	NULL
CT	NULL
)	NULL
,	NULL
and	NULL
the	NULL
specific	NULL
sense	NULL
5-CACCGGAGGGCCTGCAGGAAGCGAAT-3	NULL
'	NULL
and	NULL
antisense	NULL
CCCAGGCCTCACTTTCCAGAGGCAGC-3	NULL
'	NULL
primers	NULL
.	NULL

The	NULL
following	NULL
conditions	NULL
were	NULL
used	NULL
:	NULL
denaturation	NULL
,	NULL
1	NULL
min	NULL
at	NULL
94°C	NULL
;	NULL
annealing	NULL
,	NULL
1	NULL
min	NULL
at	NULL
60	NULL
°C	NULL
;	NULL
and	NULL
extension	NULL
,	NULL
1	NULL
min	NULL
at	NULL
72°C	NULL
for	NULL
30	NULL
cycles	NULL
.	NULL

Luciferase	NULL
Gene	NULL
Reporter	NULL
Assays	NULL
The	NULL
full	NULL
length	NULL
(	NULL
-449	NULL
to	NULL
+265	NULL
)	NULL
ECS-Iy3	NULL
region	NULL
and	NULL
its	NULL
CD4O0RE	NULL
(	NULL
-238	NULL
to	NULL
-188	NULL
)	NULL
were	NULL
cloned	NULL
into	NULL
a	NULL
pGL3	NULL
Basic	NULL
vector	NULL
and	NULL
pGL3	NULL
Promoter	NULL
vector	NULL
,	NULL
respectively	NULL
(	NULL
Schaffer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

CL-01	NULL
cells	NULL
(	NULL
16	NULL
x	NULL
105/m1	NULL
)	NULL
were	NULL
mixed	NULL
with	NULL
40	NULL
ul	NULL
of	NULL
plasmid	NULL
DNA-TE	NULL
solution	NULL
containing	NULL
20	NULL
ug	NULL
of	NULL
pGL3	NULL
vector	NULL
and	NULL
10	NULL
ng	NULL
of	NULL
pRL-CMV	NULL
control	NULL
vector	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
.	NULL

Electroporation	NULL
and	NULL
measurements	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
Schaffer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assays	NULL
B	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
6	NULL
hr	NULL
,	NULL
and	NULL
nuclear	NULL
proteins	NULL
were	NULL
extracted	NULL
using	NULL
a	NULL
modified	NULL
version	NULL
of	NULL
Schreiber	NULL
's	NULL
method	NULL
(	NULL
Schaffer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

A	NULL
double-stranded	NULL
xB1	NULL
oligonucleotide	NULL
probe	NULL
encompassing	NULL
nucleotides	NULL
-236	NULL
to	NULL
-213	NULL
of	NULL
the	NULL
Cy3	NULL
CD40RE	NULL
was	NULL
prepared	NULL
by	NULL
annealing	NULL
the	NULL
sense	NULL
primer	NULL
5-GTGTCTGGACTCCCCCTCG-3	NULL
'	NULL
to	NULL
the	NULL
antisense	NULL
primer	NULL
5	NULL
``	NULL
-AGAGGGCGAGGGGGAGTCCAGA-3	NULL
'	NULL
.	NULL

This	NULL
probe	NULL
was	NULL
labeled	NULL
with	NULL
[	NULL
a-	NULL
``	NULL
P	NULL
]	NULL
dCTP	NULL
and	NULL
[	NULL
a-	NULL
``	NULL
°P	NULL
]	NULL
dGTP	NULL
using	NULL
the	NULL
Klenow	NULL
fragment	NULL
of	NULL
DNA	NULL
polymerase	NULL
I	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

DNA	NULL
binding	NULL
reactions	NULL
and	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
12	NULL
(	NULL
Schaffer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1998	NULL
)	NULL
.	NULL

For	NULL
inhibition	NULL
assays	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
preincubated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
1	NULL
ug/ml	NULL
of	NULL
rabbit	NULL
Abs	NULL
to	NULL
human	NULL
thyreoglobulin	NULL
(	NULL
control	NULL
)	NULL
,	NULL
p50	NULL
,	NULL
p52	NULL
,	NULL
p65	NULL
(	NULL
Rel	NULL
A	NULL
)	NULL
,	NULL
c-Rel	NULL
(	NULL
Rel	NULL
)	NULL
,	NULL
or	NULL
Rel	NULL
B	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Acknowledgments	NULL
Address	NULL
all	NULL
correspondence	NULL
to	NULL
P.	NULL
C.	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
Dr.	NULL
B.	NULL
Perussia	NULL
(	NULL
Thomas	NULL
Jefferson	NULL
Cancer	NULL
Center	NULL
,	NULL
Philadelphia	NULL
,	NULL
PA	NULL
)	NULL
for	NULL
human	NULL
recombinant	NULL
IL-12	NULL
and	NULL
mouse	NULL
neutralizing	NULL
Abs	NULL
to	NULL
human	NULL
IFNy	NULL
.	NULL

We	NULL
thank	NULL
Ms.	NULL
P.	NULL
Dramitinos	NULL
for	NULL
her	NULL
skillful	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
U.	NULL
S.	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
AR	NULL
40908	NULL
and	NULL
CA	NULL
68541	NULL
to	NULL
P.	NULL
C.	NULL
References	NULL
Ansieau	NULL
S	NULL
,	NULL
Scheffrahn	NULL
I	NULL
,	NULL
Mosialos	NULL
G	NULL
,	NULL
Brand	NULL
H	NULL
,	NULL
Duyster	NULL
J	NULL
,	NULL
Kaye	NULL
K	NULL
,	NULL
Harada	NULL
J	NULL
,	NULL
Dougall	NULL
B	NULL
,	NULL
Hubinger	NULL
G	NULL
,	NULL
Kieff	NULL
E	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
associated	NULL
(	NULL
TRAF	NULL
)	NULL
-1	NULL
,	NULL
TRAF-2	NULL
,	NULL
and	NULL
TRAF-3	NULL
interact	NULL
in	NULL
vivo	NULL
with	NULL
the	NULL
CD30	NULL
cytoplasmic	NULL
domain	NULL
;	NULL
TRAF-2	NULL
mediates	NULL
CD30-induced	NULL
nuclear	NULL
factor	NULL
x	NULL
B	NULL
activation	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
.	NULL

1996	NULL
;	NULL
93:14053-14058	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8943059	NULL
]	NULL
Armitage	NULL
RJ	NULL
,	NULL
Sato	NULL
AT	NULL
,	NULL
Macduff	NULL
BM	NULL
,	NULL
Clifford	NULL
KN	NULL
,	NULL
Alpert	NULL
AR	NULL
,	NULL
Smith	NULL
A	NULL
,	NULL
Fanslow	NULL
WC	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
source	NULL
of	NULL
biologically	NULL
active	NULL
€D40	NULL
ligand	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
.	NULL

1992	NULL
;	NULL
22:2071-2076	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
1379186	NULL
]	NULL
Aruffo	NULL
A	NULL
,	NULL
Farrington	NULL
M	NULL
,	NULL
Hollenbaugh	NULL
D	NULL
,	NULL
Li	NULL
X	NULL
,	NULL
Milatovich	NULL
A	NULL
,	NULL
Nonoyama	NULL
S	NULL
,	NULL
Bajorath	NULL
J	NULL
,	NULL
Grosmaire	NULL
LS	NULL
,	NULL
Stenkamp	NULL
R	NULL
,	NULL
Nebauer	NULL
M	NULL
,	NULL
Roberts	NULL
RL	NULL
,	NULL
et	NULL
al	NULL
.	NULL

The	NULL
CD40	NULL
ligand	NULL
,	NULL
gp39	NULL
,	NULL
is	NULL
defective	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
from	NULL
patients	NULL
with	NULL
X-linked	NULL
hyper	NULL
IgM	NULL
syndrome	NULL
.	NULL

Cell	NULL
.	NULL

1993	NULL
;	NULL
72:291-300	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7678782	NULL
]	NULL
Cerutti	NULL
A	NULL
,	NULL
Zan	NULL
H	NULL
,	NULL
Schaffer	NULL
A	NULL
,	NULL
Bergsagel	NULL
L	NULL
,	NULL
Harindranath	NULL
N	NULL
,	NULL
Max	NULL
EE	NULL
,	NULL
Casali	NULL
P.	NULL
CD40	NULL
ligand	NULL
and	NULL
appropriate	NULL
cytokines	NULL
induce	NULL
switching	NULL
to	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
and	NULL
IgE	NULL
and	NULL
coordinated	NULL
germinal	NULL
center	NULL
and	NULL
plasmacytoid	NULL
phenotypic	NULL
differentiation	NULL
in	NULL
a	NULL
human	NULL
monoclonal	NULL
IgM	NULL
*	NULL
IgD*	NULL
B	NULL
cell	NULL
line	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1998	NULL
;	NULL
160:2145-2157	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9498752	NULL
]	NULL
Choe	NULL
J	NULL
,	NULL
Kim	NULL
HS	NULL
,	NULL
Zhang	NULL
X	NULL
,	NULL
Armitage	NULL
RJ	NULL
,	NULL
Choi	NULL
YS	NULL
.	NULL

Cellular	NULL
and	NULL
molecular	NULL
factors	NULL
that	NULL
regulate	NULL
the	NULL
differentiation	NULL
and	NULL
apoptosis	NULL
of	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
.	NULL

Anti-Ig	NULL
down-regulates	NULL
Fas	NULL
expression	NULL
on	NULL
CD40	NULL
ligand-stimulated	NULL
germinal	NULL
center	NULL
B	NULL
cells	NULL
and	NULL
inhibits	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1996	NULL
;	NULL
157:1006-1016	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8757604	NULL
]	NULL
Clark	NULL
EA	NULL
,	NULL
Ledbetter	NULL
JA	NULL
.	NULL

How	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
talk	NULL
to	NULL
each	NULL
other	NULL
.	NULL

Nature	NULL
.	NULL

1994	NULL
;	NULL
367:425-429	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8107800	NULL
]	NULL
Del	NULL
Prete	NULL
G	NULL
,	NULL
De	NULL
Carli	NULL
M	NULL
,	NULL
D'Elios	NULL
MM	NULL
,	NULL
Daniel	NULL
KC	NULL
,	NULL
Almerigogna	NULL
F	NULL
,	NULL
Alderson	NULL
M	NULL
,	NULL
Smith	NULL
CA	NULL
,	NULL
Thomas	NULL
E	NULL
,	NULL
Romagnani	NULL
S.	NULL
CD30-mediated	NULL
signaling	NULL
promotes	NULL
the	NULL
development	NULL
of	NULL
human	NULL
T	NULL
helper	NULL
type	NULL
2-like	NULL
T	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1995	NULL
;	NULL
182:1655-1661	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7500010	NULL
]	NULL
Duckett	NULL
CS	NULL
,	NULL
Thompson	NULL
CB	NULL
.	NULL

CD30-dependent	NULL
degradation	NULL
of	NULL
TRAF-2	NULL
:	NULL
implications	NULL
for	NULL
negative	NULL
regulation	NULL
of	NULL
TRAF	NULL
signaling	NULL
and	NULL
the	NULL
control	NULL
of	NULL
cell	NULL
survival	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

1997	NULL
;	NULL
11:2810-2821	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9353251	NULL
]	NULL
Diirkop	NULL
H	NULL
,	NULL
Latza	NULL
U	NULL
,	NULL
Hummel	NULL
M	NULL
,	NULL
Eitelbach	NULL
F	NULL
,	NULL
Seed	NULL
B	NULL
,	NULL
Stein	NULL
H.	NULL
Molecular	NULL
cloning	NULL
and	NULL
expression	NULL
of	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
nerve	NULL
growth	NULL
factor	NULL
receptor	NULL
family	NULL
that	NULL
is	NULL
characteristic	NULL
for	NULL
Hodgkin	NULL
's	NULL
disease	NULL
.	NULL

Cell	NULL
.	NULL

1992	NULL
;	NULL
68:421-427	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
1310894	NULL
]	NULL
Endo	NULL
TA	NULL
,	NULL
Masuhara	NULL
M	NULL
,	NULL
Yokkouchi	NULL
M	NULL
,	NULL
Suzuki	NULL
R	NULL
,	NULL
Sakamoto	NULL
H	NULL
,	NULL
Mitsui	NULL
K	NULL
,	NULL
Matsumoto	NULL
A	NULL
,	NULL
Tanimura	NULL
S	NULL
,	NULL
Ohtsubo	NULL
M	NULL
,	NULL
Misawa	NULL
H	NULL
,	NULL
et	NULL
al	NULL
.	NULL

A	NULL
new	NULL
protein	NULL
containing	NULL
a	NULL
SH2	NULL
domain	NULL
that	NULL
inhibits	NULL
Jak	NULL
kinases	NULL
.	NULL

Nature	NULL
.	NULL

1997	NULL
;	NULL
387:921-924	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9202126	NULL
]	NULL
Grewal	NULL
IS	NULL
,	NULL
Flawell	NULL
RA	NULL
.	NULL

A	NULL
central	NULL
role	NULL
of	NULL
CD40	NULL
ligand	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cell	NULL
responses	NULL
.	NULL

Immunol	NULL
Today	NULL
.	NULL

1996	NULL
;	NULL
17:410-414	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8854557	NULL
]	NULL
Gruss	NULL
HJ	NULL
,	NULL
Ulrich	NULL
D	NULL
,	NULL
Braddy	NULL
S	NULL
,	NULL
Armitage	NULL
RJ	NULL
,	NULL
Dower	NULL
SK	NULL
.	NULL

Recombinant	NULL
CD30	NULL
ligand	NULL
and	NULL
CD40	NULL
ligand	NULL
share	NULL
common	NULL
biological	NULL
activities	NULL
on	NULL
Hodgkin	NULL
and	NULL
Reed-Sterberg	NULL
cells	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
.	NULL

1995	NULL
;	NULL
25:2083-2089	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7621881	NULL
]	NULL
Hanissian	NULL
SH	NULL
,	NULL
Geha	NULL
R.	NULL
Jak3	NULL
is	NULL
associated	NULL
with	NULL
CD40	NULL
and	NULL
is	NULL
critical	NULL
for	NULL
CD40	NULL
induction	NULL
of	NULL
gene	NULL
expression	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

Immunity	NULL
.	NULL

1997	NULL
;	NULL
6:379-387	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9133417	NULL
]	NULL
Hodgkin	NULL
PD	NULL
,	NULL
Lee	NULL
JH	NULL
,	NULL
Lyons	NULL
AB	NULL
.	NULL

B	NULL
cell	NULL
differentiation	NULL
and	NULL
isotype	NULL
switching	NULL
is	NULL
related	NULL
to	NULL
division	NULL
cycle	NULL
number	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1996	NULL
;	NULL
184:277-281	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8691143	NULL
]	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
13	NULL
Jacquot	NULL
S	NULL
,	NULL
Kobata	NULL
T	NULL
,	NULL
Iwata	NULL
S	NULL
,	NULL
Morimoto	NULL
C	NULL
,	NULL
Schlossman	NULL
SF	NULL
.	NULL

CD154/CD40	NULL
and	NULL
€CD70/CD27	NULL
interactions	NULL
have	NULL
different	NULL
and	NULL
sequential	NULL
functions	NULL
in	NULL
T	NULL
cell-dependent	NULL
B	NULL
cell	NULL
responses	NULL
:	NULL
enhancement	NULL
of	NULL
plasma	NULL
cell	NULL
differentiation	NULL
by	NULL
CD27	NULL
signaling	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1997	NULL
;	NULL
159:2652-2657	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9300684	NULL
]	NULL
Jumper	NULL
MD	NULL
,	NULL
Splawski	NULL
JB	NULL
,	NULL
Lipsky	NULL
PE	NULL
,	NULL
Meek	NULL
K.	NULL
Ligation	NULL
of	NULL
CD40	NULL
induces	NULL
sterile	NULL
transcripts	NULL
of	NULL
multiple	NULL
Ig	NULL
H	NULL
chain	NULL
isotypes	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1993	NULL
;	NULL
152:438-445	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7506723	NULL
]	NULL
Jumper	NULL
MD	NULL
,	NULL
Nishioka	NULL
Y	NULL
,	NULL
Davies	NULL
LS	NULL
,	NULL
Lipsky	NULL
PE	NULL
,	NULL
Meek	NULL
K.	NULL
Regulation	NULL
of	NULL
human	NULL
B	NULL
cell	NULL
function	NULL
by	NULL
recombinant	NULL
CD40	NULL
ligand	NULL
and	NULL
other	NULL
TNF-related	NULL
ligands	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1995	NULL
;	NULL
155:2369-2378	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7650371	NULL
]	NULL
Jumper	NULL
MD	NULL
,	NULL
Fujita	NULL
K	NULL
,	NULL
Lipsky	NULL
PL	NULL
,	NULL
Meek	NULL
K.	NULL
A	NULL
CD30	NULL
responsive	NULL
element	NULL
in	NULL
the	NULL
germline	NULL
&	NULL
promoter	NULL
that	NULL
is	NULL
distinct	NULL
from	NULL
and	NULL
inhibitory	NULL
to	NULL
the	NULL
CD40	NULL
responsive	NULL
element	NULL
.	NULL

Mol	NULL
Immunol	NULL
.	NULL

1996	NULL
;	NULL
33:965-972	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8960121	NULL
]	NULL
Kehry	NULL
MR.	NULL
CD4O0-mediated	NULL
signaling	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

Balancing	NULL
cell	NULL
survival	NULL
,	NULL
growth	NULL
,	NULL
and	NULL
death	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1996	NULL
;	NULL
156:2345-2348	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8786287	NULL
]	NULL
Kuhné	NULL
MR	NULL
,	NULL
Robbins	NULL
M	NULL
,	NULL
Hambor	NULL
JE	NULL
,	NULL
Mackey	NULL
MF	NULL
,	NULL
Kosaka	NULL
Y	NULL
,	NULL
Nishimura	NULL
T	NULL
,	NULL
Gigley	NULL
JP	NULL
,	NULL
Noelle	NULL
RJ	NULL
,	NULL
Calderhead	NULL
DM	NULL
.	NULL

Assembly	NULL
and	NULL
regulation	NULL
of	NULL
the	NULL
CD40	NULL
receptor	NULL
complex	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1997	NULL
;	NULL
186:337-342	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9221764	NULL
]	NULL
Lee	NULL
SY	NULL
,	NULL
Lee	NULL
SY	NULL
,	NULL
Choi	NULL
Y.	NULL
TRAF-interacting	NULL
protein	NULL
(	NULL
TRIP	NULL
)	NULL
:	NULL
a	NULL
novel	NULL
component	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
(	NULL
LNFR	NULL
)	NULL
-	NULL
and	NULL
CD30-TRAF	NULL
signaling	NULL
complexes	NULL
that	NULL
inhibits	NULL
TRAF2-mediated	NULL
NF-xB	NULL
activation	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1997	NULL
;	NULL
185:1275-1285	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9104814	NULL
]	NULL
Morse	NULL
L	NULL
,	NULL
Chen	NULL
D	NULL
,	NULL
Gray	NULL
D	NULL
,	NULL
Franklin	NULL
D	NULL
,	NULL
Xiong	NULL
Y	NULL
,	NULL
Chen-Kiang	NULL
S.	NULL
Induction	NULL
of	NULL
cell	NULL
cycle	NULL
arrest	NULL
and	NULL
B	NULL
cell	NULL
terminal	NULL
differentiation	NULL
by	NULL
CDK	NULL
inhibitor	NULL
pISINK4C	NULL
and	NULL
IL-6	NULL
.	NULL

Immunity	NULL
.	NULL

1997	NULL
;	NULL
6:47-56	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9052836	NULL
]	NULL
Mueller	NULL
CGF	NULL
,	NULL
Rissoan	NULL
MF	NULL
,	NULL
Salinas	NULL
B	NULL
,	NULL
Ait-Yahia	NULL
S	NULL
,	NULL
Ravel	NULL
O	NULL
,	NULL
Bridon	NULL
JM	NULL
,	NULL
Briére	NULL
F	NULL
,	NULL
Lebecque	NULL
S	NULL
,	NULL
Liu	NULL
YJ	NULL
.	NULL

Polymerase	NULL
chain	NULL
reaction	NULL
selects	NULL
a	NULL
novel	NULL
disintegrin	NULL
proteinase	NULL
from	NULL
CD4O-activated	NULL
germinal	NULL
center	NULL
dendritic	NULL
cells	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1997	NULL
;	NULL
29:655-663	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9271581	NULL
]	NULL
Naka	NULL
T	NULL
,	NULL
Narazaki	NULL
M	NULL
,	NULL
Hirata	NULL
M	NULL
,	NULL
Matsumoto	NULL
T	NULL
,	NULL
Minamoto	NULL
S	NULL
,	NULL
Aono	NULL
A	NULL
,	NULL
Nishimoto	NULL
N	NULL
,	NULL
Kajita	NULL
T	NULL
,	NULL
Taga	NULL
T	NULL
,	NULL
Yoshizaki	NULL
K	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Structure	NULL
and	NULL
function	NULL
of	NULL
a	NULL
new	NULL
STAT-induced	NULL
STAT	NULL
inhibitor	NULL
.	NULL

Nature	NULL
.	NULL

1997	NULL
;	NULL
387:924-929	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9202127	NULL
]	NULL
O'Rourke	NULL
L	NULL
,	NULL
Tooze	NULL
R	NULL
,	NULL
Fearon	NULL
D.	NULL
Co-receptors	NULL
of	NULL
B	NULL
lymphocytes	NULL
.	NULL

Curr	NULL
Opin	NULL
Immunol	NULL
.	NULL

1997	NULL
;	NULL
9:324-329	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9203413	NULL
]	NULL
Ranheim	NULL
EA	NULL
,	NULL
Kipps	NULL
TJ	NULL
.	NULL

Activated	NULL
T	NULL
cells	NULL
induce	NULL
expression	NULL
of	NULL
B7/BB1	NULL
on	NULL
normal	NULL
or	NULL
leukemic	NULL
B	NULL
cells	NULL
through	NULL
a	NULL
CD4O0-dependent	NULL
signal	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1993	NULL
;	NULL
177:925-935	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7681471	NULL
]	NULL
Régnier	NULL
CH	NULL
,	NULL
Song	NULL
HY	NULL
,	NULL
Gao	NULL
X	NULL
,	NULL
Goeddel	NULL
DV	NULL
,	NULL
Cao	NULL
Z	NULL
,	NULL
Rothe	NULL
M.	NULL
Identification	NULL
and	NULL
characterization	NULL
of	NULL
an	NULL
IxB	NULL
kinase	NULL
.	NULL

Cell	NULL
.	NULL

1997	NULL
;	NULL
90:373-383	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9244310	NULL
]	NULL
Rothe	NULL
M	NULL
,	NULL
Sarma	NULL
V	NULL
,	NULL
Dixit	NULL
VM	NULL
,	NULL
Goeddel	NULL
DV	NULL
.	NULL

TRAF2-mediated	NULL
activation	NULL
of	NULL
NF-xB	NULL
by	NULL
TNF	NULL
receptor	NULL
2	NULL
and	NULL
CD40	NULL
.	NULL

Science	NULL
.	NULL

1995	NULL
;	NULL
269:1424-1427	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7544915	NULL
]	NULL
Rothe	NULL
M	NULL
,	NULL
Xiong	NULL
J	NULL
,	NULL
Shu	NULL
HB	NULL
,	NULL
Williamson	NULL
K	NULL
,	NULL
Goddard	NULL
A	NULL
,	NULL
Goeddel	NULL
DV	NULL
.	NULL

I-TRAF	NULL
is	NULL
a	NULL
novel	NULL
TRAF-interacting	NULL
protein	NULL
that	NULL
regulates	NULL
TRAF-mediated	NULL
signal	NULL
transduction	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
.	NULL

1996	NULL
;	NULL
93:8241-8246	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8710854	NULL
]	NULL
Schaffer	NULL
A	NULL
,	NULL
Cerutti	NULL
A	NULL
,	NULL
Zan	NULL
H	NULL
,	NULL
Max	NULL
EE	NULL
,	NULL
Casali	NULL
P.	NULL
The	NULL
ECS-Iy3	NULL
sequence	NULL
upstream	NULL
of	NULL
the	NULL
human	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
Sy3	NULL
region	NULL
is	NULL
a	NULL
functional	NULL
promoter	NULL
.	NULL

Synergistic	NULL
activation	NULL
by	NULL
CD40	NULL
ligand	NULL
and	NULL
IL-4	NULL
via	NULL
distinct	NULL
cis	NULL
regulatory	NULL
elements	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

1998	NULL
;	NULL
12	NULL
:	NULL
A1058	NULL
.	NULL

Schattner	NULL
EJ	NULL
,	NULL
Elkon	NULL
KB	NULL
,	NULL
Yoo	NULL
DH	NULL
,	NULL
Tumang	NULL
J	NULL
,	NULL
Krammer	NULL
PH	NULL
,	NULL
Crow	NULL
MK	NULL
,	NULL
Friedman	NULL
SM	NULL
.	NULL

CD40	NULL
ligation	NULL
induces	NULL
Apo-1/Fas	NULL
expression	NULL
on	NULL
human	NULL
B	NULL
lymphocytes	NULL
and	NULL
facilitates	NULL
apoptosis	NULL
through	NULL
the	NULL
Apo-1/Fas	NULL
pathway	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1995	NULL
;	NULL
182:1557-1565	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7595225	NULL
]	NULL
Schwarting	NULL
R	NULL
,	NULL
Gerdes	NULL
J	NULL
,	NULL
Diirkop	NULL
H	NULL
,	NULL
Falini	NULL
B	NULL
,	NULL
Pileri	NULL
S	NULL
,	NULL
Stein	NULL
H.	NULL
BER-H2	NULL
:	NULL
a	NULL
new	NULL
anti-Ki-1	NULL
(	NULL
CD30	NULL
)	NULL
monoclonal	NULL
antibody	NULL
directed	NULL
at	NULL
a	NULL
formol-resistant	NULL
epitope	NULL
.	NULL

Blood	NULL
.	NULL

1989	NULL
;	NULL
74:1678-1689	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
2477085	NULL
]	NULL
Smith	NULL
CA	NULL
,	NULL
Gruss	NULL
HJ	NULL
,	NULL
Davis	NULL
T	NULL
,	NULL
Anderson	NULL
D	NULL
,	NULL
Farrah	NULL
T	NULL
,	NULL
Baker	NULL
E	NULL
,	NULL
Sutherland	NULL
GR	NULL
,	NULL
Brannan	NULL
CI	NULL
,	NULL
Copeland	NULL
NG	NULL
,	NULL
Jenkins	NULL
NA	NULL
,	NULL
et	NULL
al	NULL
.	NULL

CD30	NULL
antigen	NULL
,	NULL
a	NULL
marker	NULL
for	NULL
Hodgkin	NULL
's	NULL
lymphoma	NULL
,	NULL
is	NULL
a	NULL
receptor	NULL
whose	NULL
ligand	NULL
defines	NULL
an	NULL
emerging	NULL
family	NULL
of	NULL
cytokines	NULL
with	NULL
homology	NULL
to	NULL
TNF	NULL
.	NULL

Cell	NULL
.	NULL

1993	NULL
;	NULL
73:1349-1360	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8391931	NULL
]	NULL
Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
14	NULL
Smith	NULL
CA	NULL
,	NULL
Farrah	NULL
T	NULL
,	NULL
Goodwin	NULL
RG	NULL
.	NULL

The	NULL
TNF	NULL
receptor	NULL
superfamily	NULL
of	NULL
cellular	NULL
and	NULL
viral	NULL
proteins	NULL
:	NULL
activation	NULL
,	NULL
costimulation	NULL
,	NULL
and	NULL
death	NULL
.	NULL

Cell	NULL
.	NULL

1994	NULL
;	NULL
76:959-962	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8137429	NULL
]	NULL
Song	NULL
HY	NULL
,	NULL
Rothe	NULL
M	NULL
,	NULL
Goeddel	NULL
DV	NULL
.	NULL

The	NULL
tumor	NULL
necrosis	NULL
factor-inducible	NULL
zinc	NULL
finger	NULL
protein	NULL
A20	NULL
interacts	NULL
with	NULL
TRAF1/TRAF2	NULL
and	NULL
inhibits	NULL
NF-xB	NULL
activation	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
.	NULL

1996	NULL
;	NULL
93:6721-6725	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8692885	NULL
]	NULL
Stavnezer	NULL
J	NULL
.	NULL

Antibody	NULL
class	NULL
switching	NULL
.	NULL

Adv	NULL
Immunol	NULL
.	NULL

1996	NULL
;	NULL
61:79-146	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8834495	NULL
]	NULL
Stein	NULL
H	NULL
,	NULL
Gerdes	NULL
J	NULL
,	NULL
Schwab	NULL
U	NULL
,	NULL
Lemke	NULL
H	NULL
,	NULL
Mason	NULL
DY	NULL
,	NULL
Ziegler	NULL
A	NULL
,	NULL
Schienle	NULL
W	NULL
,	NULL
Diehl	NULL
W.	NULL
Identification	NULL
of	NULL
Hodgkin	NULL
and	NULL
Sternberg-Reed	NULL
cells	NULL
as	NULL
a	NULL
unique	NULL
cell	NULL
type	NULL
derived	NULL
from	NULL
a	NULL
newly-detected	NULL
small-cell	NULL
population	NULL
.	NULL

Int	NULL
J	NULL
Cancer	NULL
.	NULL

1982	NULL
;	NULL
30:445-459	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
6754630	NULL
]	NULL
Stein	NULL
H	NULL
,	NULL
Mason	NULL
DY	NULL
,	NULL
Gerdes	NULL
J	NULL
,	NULL
O'Connor	NULL
N	NULL
,	NULL
Wainscoat	NULL
J	NULL
,	NULL
Pallesen	NULL
G	NULL
,	NULL
Gatter	NULL
K	NULL
,	NULL
Falini	NULL
B	NULL
,	NULL
Delsol	NULL
G	NULL
,	NULL
Lemke	NULL
H	NULL
,	NULL
et	NULL
al	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
Hodgkin	NULL
's	NULL
disease	NULL
associated	NULL
antigen	NULL
Ki-1	NULL
in	NULL
reactive	NULL
and	NULL
neoplastic	NULL
lymphoid	NULL
tissue	NULL
:	NULL
evidence	NULL
that	NULL
Reed-Sternberg	NULL
cells	NULL
and	NULL
histiocytic	NULL
malignancies	NULL
are	NULL
derived	NULL
from	NULL
activated	NULL
lymphoid	NULL
cells	NULL
.	NULL

Blood	NULL
.	NULL

1985	NULL
;	NULL
66:848-858	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
3876124	NULL
]	NULL
Stuber	NULL
E	NULL
,	NULL
Neurath	NULL
M	NULL
,	NULL
Calderhead	NULL
D	NULL
,	NULL
Fell	NULL
HP	NULL
,	NULL
Strober	NULL
W.	NULL
Cross-linking	NULL
of	NULL
OX40O	NULL
ligand	NULL
,	NULL
a	NULL
member	NULL
of	NULL
the	NULL
TNE/NGF	NULL
cytokine	NULL
family	NULL
,	NULL
induces	NULL
proliferation	NULL
and	NULL
differentiation	NULL
in	NULL
murine	NULL
splenic	NULL
B	NULL
cells	NULL
.	NULL

Immunity	NULL
.	NULL

1995	NULL
;	NULL
2:507-521	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7749983	NULL
]	NULL
Takai	NULL
T	NULL
,	NULL
Ono	NULL
M	NULL
,	NULL
Hikida	NULL
M	NULL
,	NULL
Ohmori	NULL
H	NULL
,	NULL
Ravetch	NULL
JV	NULL
.	NULL

Augmented	NULL
humoral	NULL
and	NULL
anaphylactic	NULL
responses	NULL
in	NULL
FeyRII-deficient	NULL
mice	NULL
.	NULL

Nature	NULL
.	NULL

1996	NULL
;	NULL
379:346-349	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8552190	NULL
]	NULL
Tivol	NULL
EA	NULL
,	NULL
Borriello	NULL
F	NULL
,	NULL
Schweitzer	NULL
AN	NULL
,	NULL
Lynch	NULL
WP	NULL
,	NULL
Bluestone	NULL
JA	NULL
,	NULL
Sharpe	NULL
AH	NULL
.	NULL

Loss	NULL
of	NULL
CTLA-4	NULL
leads	NULL
to	NULL
massive	NULL
lymphoproliferation	NULL
and	NULL
fatal	NULL
multiorgan	NULL
tissue	NULL
destruction	NULL
,	NULL
revealing	NULL
a	NULL
critical	NULL
negative	NULL
regulatory	NULL
role	NULL
of	NULL
CTLA-4	NULL
.	NULL

Immunity	NULL
.	NULL

1995	NULL
;	NULL
3:541-547	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
7584144	NULL
]	NULL
Van	NULL
Kooten	NULL
C	NULL
,	NULL
Banchereau	NULL
J.	NULL
CD40-CD40	NULL
ligand	NULL
:	NULL
a	NULL
multifunctional	NULL
receptor-ligand	NULL
pair	NULL
.	NULL

Adv	NULL
Immunol	NULL
.	NULL

1996	NULL
;	NULL
61:1-77	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8834494	NULL
]	NULL
Walunas	NULL
TL	NULL
,	NULL
Baker	NULL
CY	NULL
,	NULL
Bluestone	NULL
JA	NULL
.	NULL

CTLA-4	NULL
ligation	NULL
blocks	NULL
CD28-dependent	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

J	NULL
Exp	NULL
Med	NULL
.	NULL

1996	NULL
;	NULL
183:2541-2550	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
8676075	NULL
]	NULL
Yoshimoto	NULL
T	NULL
,	NULL
Okamura	NULL
H	NULL
,	NULL
Tagawa	NULL
YI	NULL
,	NULL
Iwakura	NULL
Y	NULL
,	NULL
Nakanishi	NULL
K.	NULL
Interleukin	NULL
18	NULL
together	NULL
with	NULL
interleukin	NULL
12	NULL
inhibits	NULL
IgE	NULL
production	NULL
by	NULL
induction	NULL
of	NULL
interferon-y	NULL
production	NULL
from	NULL
activated	NULL
B	NULL
cells	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
.	NULL

1997	NULL
;	NULL
95:3948-3953	NULL
.	NULL

[	NULL
PubMed	NULL
:	NULL
9108085	NULL
]	NULL
Zan	NULL
H	NULL
,	NULL
Cerutti	NULL
A	NULL
,	NULL
Dramitinos	NULL
P	NULL
,	NULL
Schaffer	NULL
A	NULL
,	NULL
Casali	NULL
P.	NULL
CD40	NULL
engagement	NULL
triggers	NULL
switching	NULL
to	NULL
IgA1	NULL
and	NULL
Ig	NULL
A2	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
other	NULL
stimuli	NULL
and	NULL
through	NULL
the	NULL
induction	NULL
of	NULL
endogenous	NULL
TGFB	NULL
.	NULL

Evidence	NULL
for	NULL
TGFB	NULL
dependent	NULL
but	NULL
not	NULL
IL-10-dependent	NULL
direct	NULL
Su-Sa	NULL
and	NULL
sequential	NULL
Su-Sy	NULL
,	NULL
Sy-Sqa	NULL
DNA	NULL
recombination	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

1998a	NULL
in	NULL
press	NULL
.	NULL

Zan	NULL
H	NULL
,	NULL
Cerutti	NULL
A	NULL
,	NULL
Dramitinos	NULL
P	NULL
,	NULL
Schaffer	NULL
A	NULL
,	NULL
Li	NULL
Z	NULL
,	NULL
Casali	NULL
P.	NULL
Induction	NULL
of	NULL
coordinated	NULL
Ig	NULL
somatic	NULL
hypermutation	NULL
and	NULL
class	NULL
switching	NULL
in	NULL
a	NULL
human	NULL
monoclonal	NULL
model	NULL
of	NULL
germinal	NULL
center	NULL
B	NULL
cell	NULL
differentiation	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

1998b	NULL
;	NULL
12	NULL
:	NULL
¥1057	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

10°	NULL
II'J1	NULL
10°	NULL
10°	NULL
10°	NULL
CD30	NULL
B	NULL
ta	NULL
(	NULL
10°	NULL
ao	NULL
``	NULL
10°	NULL
10°	NULL
308	NULL
CD40	NULL
f	NULL
‘	NULL
{	NULL
--	NULL
+	NULL
MOPC21	NULL
mAb	NULL
1	NULL
i	NULL
tI	NULL
J	NULL
]	NULL
,	NULL
—	NULL
+	NULL
anti-CD30	NULL
mAb	NULL
A\	NULL
\	NULL
J	NULL
1	NULL
I	NULL
%	NULL
C	NULL
MOPC21	NULL
-	NULL
Anti-CD30	NULL
mAb	NULL
mAb	NULL
hCD40L	NULL
-	NULL
-	NULL
+	NULL
+	NULL
-	NULL
-	NULL
404	NULL
IL-4	NULL
=o¥	NULL
_	NULL
#	NULL
_c	NULL
+	NULL
+	NULL
JCp	NULL
Iyl-Cy1	NULL
s-Cyd	NULL
lo2.Co2	NULL
Ie-Ce	NULL
B-actin	NULL
D	NULL
MOPC21	NULL
Anti-CD30	NULL
mAb	NULL
mAb	NULL
con	NULL
+	NULL
+	NULL
=	NULL
%	NULL
%	NULL
FR3.Cu	NULL
FR3-Cy	NULL
FR3.CP	NULL
FRB	NULL
FR3-Cm	NULL
FR3.CocI	NULL
FR3-.Co2	NULL
FR3-C	NULL
B-actin	NULL
I	NULL
4	NULL
I	NULL
+	NULL
I	NULL
I	NULL
Page	NULL
15	NULL
Figure	NULL
1.	NULL
sIgM	NULL
*sIgD*	NULL
CL-01	NULL
B	NULL
Cells	NULL
Express	NULL
Surface	NULL
CD30	NULL
Whose	NULL
Engagement	NULL
Negatively	NULL
Modulates	NULL
CD40L	NULL
and	NULL
IL-4-Induced	NULL
Switching	NULL
to	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
and	NULL
IgE	NULL
but	NULL
Not	NULL
Surface	NULL
CD40	NULL
Expression	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
Upon	NULL
incubation	NULL
for	NULL
2	NULL
days	NULL
in	NULL
medium	NULL
only	NULL
or	NULL
in	NULL
medium	NULL
containing	NULL
0.5	NULL
ug/	NULL
ml	NULL
of	NULL
htCD40L	NULL
,	NULL
5	NULL
ug/ml	NULL
!	NULL

of	NULL
control	NULL
MOPC-21	NULL
MAb	NULL
,	NULL
or	NULL
5	NULL
ug/ml	NULL
of	NULL
MAb	NULL
to	NULL
human	NULL
CD30	NULL
,	NULL
CL-O01	NULL
cells	NULL
were	NULL
analyzed	NULL
for	NULL
expression	NULL
of	NULL
surface	NULL
CD30	NULL
or	NULL
CD40	NULL
.	NULL

(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
CL-O1	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
5	NULL
days	NULL
in	NULL
medium	NULL
only	NULL
or	NULL
in	NULL
medium	NULL
containing	NULL
IL-4	NULL
alone	NULL
(	NULL
100	NULL
U/ml	NULL
)	NULL
,	NULL
htCD4O0L	NULL
alone	NULL
(	NULL
0.5	NULL
ug/ml	NULL
)	NULL
,	NULL
or	NULL
htCD4O0L	NULL
and	NULL
IL-4	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
either	NULL
MOPC-21	NULL
or	NULL
anti-CD30	NULL
MAbs	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
template	NULL
cDNA	NULL
were	NULL
used	NULL
to	NULL
PCR	NULL
amplify	NULL
Iq-Cy	NULL
(	NULL
C	NULL
)	NULL
,	NULL
VgDJy-Cy	NULL
(	NULL
D	NULL
)	NULL
,	NULL
and	NULL
B-actin	NULL
transcripts	NULL
(	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Amplified	NULL
products	NULL
were	NULL
then	NULL
fractionated	NULL
into	NULL
2	NULL
%	NULL
ethidium	NULL
bromide-stained	NULL
agarose	NULL
gel	NULL
.	NULL

These	NULL
findings	NULL
were	NULL
derived	NULL
from	NULL
one	NULL
of	NULL
three	NULL
experiments	NULL
yielding	NULL
comparable	NULL
results	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
16	NULL
Nil	NULL
0	NULL
CD71	NULL
CD80	NULL
CD86	NULL
CD95	NULL
|	NULL
l	NULL
|	NULL
|	NULL
HM	NULL
\	NULL
\	NULL
T	NULL
p	NULL
war	NULL
Rrorralft	NULL
rense	NULL
102	NULL
-	NULL
30°	NULL
-	NULL
ao	NULL
``	NULL
B	NULL
htCD40L	NULL
75|	NULL
CD71	NULL
CD80	NULL
_	NULL
CD86	NULL
CD95	NULL
2	NULL
A	NULL
W	NULL
2.10	NULL
0	NULL
``	NULL
G	NULL
``	NULL
od	NULL
Of	NULL
on	NULL
gt	NULL
(	NULL
C	NULL
htCD40L+	NULL
anti-BCR	NULL
mAbs	NULL
g	NULL
CD71	NULL
CD80	NULL
_	NULL
CD86	NULL
_	NULL
CD95	NULL
o	NULL
&	NULL
e	NULL
:	NULL
10	NULL
%	NULL
ao	NULL
)	NULL
as	NULL
CD30	NULL
Figure	NULL
2	NULL
.	NULL

Normal	NULL
sIgM	NULL
*sIgD*	NULL
B	NULL
Cells	NULL
Express	NULL
CD30	NULL
mRNA	NULL
,	NULL
Surface	NULL
CD30	NULL
,	NULL
and	NULL
GC	NULL
Markers	NULL
upon	NULL
CD40	NULL
Engagement	NULL
by	NULL
CD40L	NULL
;	NULL
BCR	NULL
Coengagement	NULL
Down-Regulates	NULL
Surface	NULL
CD30	NULL
Expression	NULL
Naive	NULL
B	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
3	NULL
days	NULL
in	NULL
medium	NULL
only	NULL
(	NULL
A	NULL
)	NULL
or	NULL
in	NULL
medium	NULL
containing	NULL
0.5	NULL
ug/ml	NULL
of	NULL
htCD40L	NULL
(	NULL
B	NULL
)	NULL
or	NULL
htCD4O0L	NULL
and	NULL
2	NULL
ug/ml	NULL
of	NULL
anti-x	NULL
and	NULL
anti-A	NULL
chain	NULL
(	NULL
anti-BCR	NULL
)	NULL
MAbs	NULL
(	NULL
C	NULL
)	NULL
and	NULL
then	NULL
analyzed	NULL
for	NULL
expression	NULL
of	NULL
surface	NULL
CD19	NULL
,	NULL
CD30	NULL
,	NULL
CD71	NULL
,	NULL
CD80	NULL
,	NULL
CD86	NULL
,	NULL
and	NULL
CD95	NULL
.	NULL

B-actin	NULL
and	NULL
CD30	NULL
cDNAs	NULL
from	NULL
the	NULL
same	NULL
cells	NULL
were	NULL
PCR	NULL
amplified	NULL
and	NULL
fractioned	NULL
into	NULL
a	NULL
2	NULL
%	NULL
ethidium	NULL
bromide-stained	NULL
agarose	NULL
gel	NULL
.	NULL

These	NULL
findings	NULL
were	NULL
derived	NULL
from	NULL
one	NULL
of	NULL
five	NULL
experiments	NULL
yielding	NULL
comparable	NULL
results	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Page	NULL
17	NULL
90	NULL
ONil	NULL
_	NULL
F	NULL
htCDA4OL	NULL
80	NULL
|	NULL
i	NULL
bok	NULL
|	NULL
L	NULL
70	NULL
&	NULL
aa	NULL
-	NULL
60	NULL
ics	NULL
2	NULL
|	NULL
m	NULL
-	NULL
504	NULL
3	NULL
D40	NULL
T	NULL
U	NULL
1	NULL
530—	NULL
A	NULL
O	NULL
204	NULL
10	NULL
4	NULL
i	NULL
-_II_-l	NULL
--	NULL
I	NULL
--	NULL
II	NULL
§Qﬁﬁhcmﬁasn5§§	NULL
Tol	NULL
Q	NULL
l	NULL
To	NULL
u	NULL
s	NULL
p	NULL
c	NULL
Limh—	NULL
‘	NULL
daiégqﬁ	NULL
m	NULL
anti-BCR	NULL
mAbs	NULL
gg	NULL
anti-BCR	NULL
mAbs	NULL
[	NULL
7	NULL
+	NULL
IL-6	NULL
+	NULL
IL-12	NULL
Figure	NULL
3	NULL
.	NULL

Stimuli	NULL
Other	NULL
than	NULL
CD40L	NULL
Do	NULL
Not	NULL
Induce	NULL
CD30	NULL
Expression	NULL
in	NULL
Normal	NULL
sIgM	NULL
*sIgD*	NULL
B	NULL
Cells	NULL
Naive	NULL
B	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
3	NULL
days	NULL
in	NULL
medium	NULL
only	NULL
or	NULL
in	NULL
medium	NULL
containing	NULL
IL-1	NULL
$	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
,	NULL
IL-2	NULL
(	NULL
200	NULL
U/ml	NULL
)	NULL
,	NULL
IL-4	NULL
(	NULL
200	NULL
U/ml	NULL
!	NULL
)	NULL

,	NULL
IL-7	NULL
(	NULL
100	NULL
U/ml	NULL
)	NULL
,	NULL
IL-10	NULL
(	NULL
200	NULL
ng/ml	NULL
)	NULL
,	NULL
IL-13	NULL
(	NULL
5	NULL
ng/	NULL
ml	NULL
)	NULL
,	NULL
IFNy	NULL
(	NULL
200	NULL
U/m	NULL
!	NULL
)	NULL

,	NULL
IFNa	NULL
(	NULL
200	NULL
U/ml	NULL
)	NULL
,	NULL
TNFa	NULL
(	NULL
2.5	NULL
ng/ml	NULL
)	NULL
,	NULL
LTB	NULL
(	NULL
2.5	NULL
ng/ml	NULL
)	NULL
,	NULL
(	NULL
0.5	NULL
ng/	NULL
ml	NULL
)	NULL
,	NULL
IL-6	NULL
(	NULL
200	NULL
ng/m	NULL
!	NULL
)	NULL

,	NULL
IL-12	NULL
(	NULL
1	NULL
ng/ml	NULL
!	NULL
)	NULL

,	NULL
immobilized	NULL
anti-x	NULL
and	NULL
anti-A	NULL
(	NULL
anti-BCR	NULL
)	NULL
MAbs	NULL
(	NULL
2	NULL
ug/ml	NULL
each	NULL
)	NULL
,	NULL
and	NULL
a	NULL
combination	NULL
of	NULL
IL-6	NULL
,	NULL
IL-12	NULL
,	NULL
and	NULL
anti-BCR	NULL
Ab	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
full	NULL
histograms	NULL
)	NULL
or	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
open	NULL
histograms	NULL
)	NULL
of	NULL
htCD4OL	NULL
(	NULL
0.5	NULL
ug/ml	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
reacted	NULL
with	NULL
FITC-conjugated	NULL
anti-CD30	NULL
MAb	NULL
and	NULL
PE-conjugated	NULL
anti-CD19	NULL
MAbs	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometric	NULL
analysis	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
CD19*CD30*	NULL
B	NULL
cells	NULL
corresponds	NULL
to	NULL
the	NULL
proportion	NULL
of	NULL
cells	NULL
reacted	NULL
with	NULL
the	NULL
above	NULL
MAbs	NULL
that	NULL
display	NULL
a	NULL
fluorescence	NULL
intensity	NULL
higher	NULL
than	NULL
that	NULL
displayed	NULL
by	NULL
similar	NULL
cells	NULL
reacted	NULL
with	NULL
control	NULL
FITC-	NULL
and	NULL
PE-conjugated	NULL
isotype	NULL
matched	NULL
MAbs	NULL
.	NULL

Values	NULL
are	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
three	NULL
determinations	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
18	NULL
CI	NULL
MOPC-21	NULL
mab	NULL
l	NULL
Anti-CD30	NULL
mAb	NULL
IgM	NULL
___	NULL
1	NULL
df	NULL
[	NULL
IeG	NULL
_______	NULL
[	NULL
IsA	NULL
___	NULL
___	NULL
,	NULL
|	NULL
\	NULL
[	NULL
Ie8	NULL
___	NULL
___	NULL
JDNA	NULL
it	NULL
synthesis	NULL
;	NULL
J	NULL
Cytokines	NULL
=	NULL
htCD40L	NULL
=	NULL
Anti-BCR	NULL
mAbs	NULL
~	NULL
Ro	NULL
;	NULL
|	NULL
Cm	NULL
4	NULL
1	NULL
++	NULL
+++	NULL
ra	NULL
a	NULL
ba	NULL
+	NULL
14	NULL
a	NULL
1	NULL
++	NULL
+++	NULL
ba	NULL
d	NULL
Figure	NULL
4	NULL
.	NULL

CD30	NULL
Engagement	NULL
in	NULL
the	NULL
Absence	NULL
of	NULL
BCR	NULL
Coengagement	NULL
Inhibits	NULL
Ig	NULL
Class	NULL
Switching	NULL
but	NULL
Not	NULL
Proliferation	NULL
in	NULL
Normal	NULL
sIgM	NULL
*sIgD*	NULL
B	NULL
Cells	NULL
Exposed	NULL
to	NULL
CD40L	NULL
and	NULL
Appropriate	NULL
Cytokines	NULL
Naive	NULL
B	NULL
cells	NULL
were	NULL
preincubated	NULL
for	NULL
2	NULL
days	NULL
with	NULL
medium	NULL
only	NULL
,	NULL
htCD4O0L	NULL
(	NULL
0.5	NULL
ug/ml1	NULL
)	NULL
,	NULL
or	NULL
htCD40L	NULL
and	NULL
immobilized	NULL
anti-	NULL
and	NULL
anti-A	NULL
chain	NULL
(	NULL
anti-BCR	NULL
)	NULL
MAbs	NULL
(	NULL
2	NULL
ug/ml	NULL
each	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
harvested	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
seeded	NULL
in	NULL
culture	NULL
plates	NULL
coated	NULL
with	NULL
either	NULL
MOPC-21	NULL
(	NULL
open	NULL
histograms	NULL
)	NULL
or	NULL
anti-CD30	NULL
(	NULL
full	NULL
histograms	NULL
)	NULL
MAbs	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
medium	NULL
only	NULL
or	NULL
medium	NULL
containing	NULL
IL-4	NULL
(	NULL
100	NULL
U/ml	NULL
!	NULL
)	NULL

and	NULL
IL-10	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
;	NULL
htCD4O0L	NULL
;	NULL
or	NULL
htCD40L	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
IL-10	NULL
.	NULL

In	NULL
selected	NULL
experiments	NULL
,	NULL
TGFBI	NULL
(	NULL
0.5	NULL
ng/ml	NULL
)	NULL
was	NULL
added	NULL
to	NULL
htCD40L	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
IL-10	NULL
to	NULL
optimize	NULL
IgA	NULL
secretion	NULL
.	NULL

After	NULL
8	NULL
days	NULL
,	NULL
the	NULL
concentration	NULL
of	NULL
IgM	NULL
,	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
and	NULL
IgE	NULL
in	NULL
the	NULL
culture	NULL
fluids	NULL
was	NULL
measured	NULL
by	NULL
ELISA	NULL
.	NULL

To	NULL
measure	NULL
DNA	NULL
synthesis	NULL
,	NULL
B	NULL
cells	NULL
(	NULL
1	NULL
x	NULL
10°/well	NULL
)	NULL
were	NULL
cultured	NULL
as	NULL
above	NULL
for	NULL
5	NULL
days	NULL
and	NULL
then	NULL
pulsed	NULL
for	NULL
18	NULL
hr	NULL
with	NULL
[	NULL
PH	NULL
]	NULL
JTdR	NULL
.	NULL

B	NULL
cells	NULL
were	NULL
harvested	NULL
at	NULL
day	NULL
3	NULL
and	NULL
counted	NULL
(	NULL
200	NULL
cells	NULL
)	NULL
by	NULL
trypan	NULL
blue	NULL
dye	NULL
exclusion	NULL
to	NULL
measure	NULL
cell	NULL
viability	NULL
.	NULL

Values	NULL
are	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
four	NULL
determinations	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
19	NULL
A	NULL
wt	NULL
BECS-Iy3	NULL
(	NULL
-449	NULL
/	NULL
+265	NULL
)	NULL
B	NULL
-	NULL
ross	NULL
cDaore	NULL
(	NULL
238/183	NULL
)	NULL
-449	NULL
-238-233-199	NULL
-65	NULL
+1	NULL
.	NULL

+265	NULL
-238	NULL
233	NULL
223	NULL
-208	NULL
-199	NULL
~188	NULL
ECs	NULL
_	NULL
...	NULL
CDORE	NULL
_	NULL
(	NULL
HA	NULL
___	NULL
]	NULL
p	NULL
V	NULL
CD40RE	NULL
xB1	NULL
xB2	NULL
[	NULL
-	NULL
]	NULL
MOPC21	NULL
mAb	NULL
EH	NULL
Anti-CD30	NULL
mAb	NULL
C	NULL
)	NULL
MOPC21	NULL
mAb	NULL
BK	NULL
Anti-CD30	NULL
mAb	NULL
i	NULL
§	NULL
3	NULL
§	NULL
is	NULL
S	NULL
4	NULL
3	NULL
3	NULL
B	NULL
a	NULL
3	NULL
>	NULL
A	NULL
%	NULL
&	NULL
1	NULL
1	NULL
IL-4	NULL
-	NULL
+	NULL
-	NULL
+	NULL
+	NULL
IL-4	NULL
x	NULL
+	NULL
-	NULL
+	NULL
#	NULL
hiCD40L	NULL
-_	NULL
-	NULL
w	NULL
+	NULL
+	NULL
+	NULL
RiCD40L	NULL
-	NULL
-	NULL
2	NULL
*	NULL
h	NULL
7	NULL
1	NULL
Anti-IFN-yAb	NULL
=	NULL
--	NULL
-=	NULL
--	NULL
=	NULL
-	NULL
+	NULL
Anti-IFN-y	NULL
Ab	NULL
-	NULL
a	NULL
--	NULL
A	NULL
~	NULL
+	NULL
Figure	NULL
5	NULL
.	NULL

CD30	NULL
Engagement	NULL
Down-Regulates	NULL
the	NULL
CD40-Mediated	NULL
NF-xB-Dependent	NULL
Activation	NULL
of	NULL
the	NULL
Human	NULL
Cy3	NULL
Germline	NULL
Gene	NULL
Promoter	NULL
CL-O01	NULL
cells	NULL
were	NULL
transiently	NULL
cotransfected	NULL
with	NULL
a	NULL
pRL-CMV	NULL
control	NULL
luciferase	NULL
plasmid	NULL
and	NULL
either	NULL
a	NULL
wild-type	NULL
(	NULL
wt	NULL
)	NULL
ECS-Iy3-pGL3	NULL
(	NULL
LUC	NULL
)	NULL
plasmid	NULL
(	NULL
A	NULL
)	NULL
or	NULL
an	NULL
ECS-Iy3	NULL
CD4O0RE-SV40-pGL3	NULL
(	NULL
LUC	NULL
)	NULL
minimal	NULL
promoter	NULL
plasmid	NULL
(	NULL
B	NULL
)	NULL
.	NULL

The	NULL
top	NULL
graphics	NULL
depict	NULL
the	NULL
organization	NULL
of	NULL
these	NULL
constructs	NULL
.	NULL

The	NULL
initiation	NULL
of	NULL
transcription	NULL
within	NULL
the	NULL
wt	NULL
ECS-Iy3	NULL
promoter	NULL
is	NULL
indicated	NULL
by	NULL
an	NULL
arrow	NULL
,	NULL
and	NULL
numbering	NULL
is	NULL
such	NULL
that	NULL
+1	NULL
corresponds	NULL
to	NULL
the	NULL
first	NULL
residue	NULL
after	NULL
this	NULL
initiation	NULL
site	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
B	NULL
cells	NULL
were	NULL
seeded	NULL
in	NULL
culture	NULL
plates	NULL
coated	NULL
with	NULL
either	NULL
MOPC-21	NULL
(	NULL
open	NULL
histograms	NULL
)	NULL
or	NULL
agonistic	NULL
anti-CD30	NULL
MAbs	NULL
(	NULL
full	NULL
histograms	NULL
)	NULL
in	NULL
medium	NULL
only	NULL
or	NULL
in	NULL
medium	NULL
containing	NULL
IL-4	NULL
(	NULL
500	NULL
U/ml	NULL
)	NULL
;	NULL
htCD40L	NULL
(	NULL
0.5	NULL
ug/ml	NULL
!	NULL
)	NULL

;	NULL
htCD40L	NULL
and	NULL
IL-4	NULL
;	NULL
or	NULL
htCD4O0L	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
anti-IFNy	NULL
Abs	NULL
(	NULL
1:500	NULL
)	NULL
.	NULL

Luciferase	NULL
activity	NULL
was	NULL
measured	NULL
after	NULL
24	NULL
hr	NULL
.	NULL

Values	NULL
are	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
20	NULL
A	NULL
ECS-Iy3	NULL
CD40RE	NULL
26	NULL
Bl	NULL
site	NULL
B2	NULL
site	NULL
-194	NULL
CTGTGTCTGGACTCCCCCITCGCCCTCTGACACAGAAACCACCAGAA	NULL
a	NULL
rmmod	NULL
B	NULL
E	NULL
KBI	NULL
probe	NULL
&	NULL
.	NULL

B	NULL
3	NULL
,	NULL
-o-	NULL
pom	NULL
o-	NULL
-o	NULL
m-	NULL
is	NULL
ong	NULL
Cm	NULL
ece	NULL
Anti-CD30	NULL
mAb	NULL
E	NULL
_o	NULL
$	NULL
o	NULL
go-	NULL
o-	NULL
$	NULL
go	NULL
-	NULL
bop	NULL
bog	NULL
¥	NULL
2	NULL
X	NULL
&	NULL
m	NULL
hiCD40L	NULL
go	NULL
o-	NULL
o-	NULL
-	NULL
-	NULL
$	NULL
$	NULL
o	NULL
o	NULL
$	NULL
o	NULL
$	NULL
o	NULL
>	NULL
§	NULL
§	NULL
t	NULL
=	NULL
l-g.	NULL
rt	NULL
;	NULL
-	NULL
EC	NULL
:	NULL
a	NULL
?	NULL

E	NULL
Cycloheximide	NULL
$	NULL
0.2	NULL
.	NULL

go-	NULL
gpo	NULL
-	NULL
o	NULL
$	NULL
-	NULL
go-	NULL
E	NULL
E	NULL
f	NULL
?	NULL

A	NULL
“	NULL
;	NULL
2	NULL
g	NULL
g	NULL
``	NULL
é	NULL
:	NULL
E	NULL
Anti-CD27	NULL
mAb	NULL
&	NULL
=	NULL
'	NULL
m	NULL
(	NULL
u	NULL
m-	NULL
u.	NULL
k	NULL
-	NULL
(	NULL
$	NULL
(	NULL
Q	NULL
Q	NULL
Q	NULL
B	NULL
G	NULL
:	NULL
@	NULL
@	NULL
<	NULL
a	NULL
Complex	NULL
A	NULL
(	NULL
p50/p6S	NULL
)	NULL
-	NULL
I-Complex	NULL
B	NULL
i	NULL
»	NULL
N	NULL
’	NULL
(	NULL
p50/c-Rel	NULL
)	NULL
Complex	NULL
C	NULL
(	NULL
pS0/p50	NULL
)	NULL
1	NULL
%	NULL
3	NULL
4	NULL
5	NULL
6	NULL
1	NULL
8	NULL
9	NULL
10	NULL
I1	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
18	NULL
%	NULL
19	NULL
Figure	NULL
6	NULL
.	NULL

CD30	NULL
Engagement	NULL
Down-Regulates	NULL
the	NULL
CD40-Mediated	NULL
Binding	NULL
of	NULL
NF-xB	NULL
to	NULL
the	NULL
CD40RE	NULL
of	NULL
the	NULL
Human	NULL
Cy3	NULL
Germline	NULL
Gene	NULL
Promoter	NULL
(	NULL
A	NULL
)	NULL
Sequence	NULL
of	NULL
the	NULL
ECS-Iy3	NULL
CD4O0RE	NULL
encompassed	NULL
by	NULL
the	NULL
B1	NULL
probe	NULL
.	NULL

The	NULL
two	NULL
xB	NULL
sites	NULL
within	NULL
the	NULL
CD4O0RE	NULL
are	NULL
boxed	NULL
.	NULL

(	NULL
B	NULL
)	NULL
CL-O01	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
MOPC-21	NULL
MAb	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
,	NULL
anti-CD30	NULL
MAb	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
,	NULL
MOPC-21	NULL
MAb	NULL
and	NULL
htCD4OL	NULL
(	NULL
0.5	NULL
ug/ml1	NULL
)	NULL
,	NULL
anti-CD30	NULL
MAb	NULL
and	NULL
htCD4OL	NULL
,	NULL
or	NULL
anti-CD27	NULL
MAb	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
and	NULL
htCD4O0L	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
100	NULL
ug/ml	NULL
!	NULL

of	NULL
cycloheximide	NULL
(	NULL
CHX	NULL
)	NULL
.	NULL

Nuclear	NULL
proteins	NULL
were	NULL
extracted	NULL
after	NULL
6	NULL
hr	NULL
of	NULL
culture	NULL
,	NULL
incubated	NULL
with	NULL
a	NULL
radiolabeled	NULL
xB1	NULL
oligonucleotide	NULL
for	NULL
30	NULL
min	NULL
,	NULL
and	NULL
then	NULL
fractionated	NULL
through	NULL
a	NULL
6	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
(	NULL
lanes	NULL
2-10	NULL
;	NULL
lane	NULL
1	NULL
corresponds	NULL
to	NULL
the	NULL
protein-free	NULL
probe	NULL
)	NULL
.	NULL

The	NULL
specificity	NULL
of	NULL
shifted	NULL
complexes	NULL
A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
C	NULL
,	NULL
and	NULL
their	NULL
identity	NULL
to	NULL
NF-xB	NULL
complexes	NULL
were	NULL
established	NULL
by	NULL
pre-incubating	NULL
nuclear	NULL
proteins	NULL
from	NULL
CD4O0L-induced	NULL
cells	NULL
with	NULL
competitors	NULL
1	NULL
(	NULL
unlabeled	NULL
xB1	NULL
probe	NULL
)	NULL
,	NULL
2	NULL
(	NULL
unlabeled	NULL
xB1	NULL
mutant	NULL
)	NULL
,	NULL
and	NULL
3	NULL
(	NULL
palindromic	NULL
NF-	NULL
«	NULL
<	NULL
B	NULL
binding	NULL
sequence	NULL
from	NULL
the	NULL
Ig	NULL
x	NULL
promoter	NULL
)	NULL
(	NULL
lanes	NULL
11-13	NULL
)	NULL
.	NULL

The	NULL
composition	NULL
of	NULL
complexes	NULL
A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
C	NULL
was	NULL
determined	NULL
by	NULL
preincubating	NULL
nuclear	NULL
proteins	NULL
with	NULL
rabbit	NULL
Abs	NULL
to	NULL
human	NULL
thyreoglobulin	NULL
(	NULL
control	NULL
)	NULL
,	NULL
p50	NULL
,	NULL
p52	NULL
,	NULL
p65	NULL
,	NULL
c-Rel	NULL
,	NULL
or	NULL
Rel	NULL
B	NULL
proteins	NULL
(	NULL
lanes	NULL
14-19	NULL
)	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26.	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuepj	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
iduosnuep	NULL
1oyiny	NULL
Cerutti	NULL
et	NULL
al	NULL
.	NULL

Page	NULL
21	NULL
Naive	NULL
B	NULL
cell	NULL
Germinal	NULL
center	NULL
B	NULL
cell	NULL
Dendritic	NULL
cell	NULL
_	NULL
<	NULL
am	NULL
»	NULL
p	NULL
4	NULL
*	NULL
wao.i	NULL
>	NULL
IL-12	NULL
o	NULL
As	NULL
Ig	NULL
class	NULL
loG	NULL
-	NULL
>	NULL
*	NULL
<	NULL
®	NULL
switching	NULL
5c	NULL
sec	NULL
IgA	NULL
T*	NULL
T*	NULL
*e	NULL
sec	NULL
IL-6	NULL
=	NULL
-a	NULL
-c	NULL
IL-4	NULL
a	NULL
®	NULL
-	NULL
<	NULL
IgE	NULL
o	NULL
-	NULL
&	NULL
BCR	NULL
20°	NULL
Activated	NULL
1L-10	NULL
,	NULL
T	NULL
cell	NULL
CD40	NULL
Q	NULL
CD40L	NULL
CD30L	NULL
CD40	NULL
CD30	NULL
Block	NULL
of	NULL
Ig	NULL
class	NULL
switching	NULL
x	NULL
*	NULL
’	NULL
IgM	NULL
No	NULL
Ag	NULL
Figure	NULL
7	NULL
.	NULL

Role	NULL
of	NULL
CD30	NULL
in	NULL
the	NULL
Regulation	NULL
of	NULL
Human	NULL
CD40-Dependent	NULL
B	NULL
Cell	NULL
Differentiation	NULL
In	NULL
the	NULL
upper	NULL
limb	NULL
of	NULL
the	NULL
scheme	NULL
,	NULL
a	NULL
naive	NULL
CD30	NULL
B	NULL
cell	NULL
differentiates	NULL
into	NULL
a	NULL
GC	NULL
B	NULL
cell	NULL
and	NULL
undergoes	NULL
switching	NULL
to	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
or	NULL
IgE	NULL
upon	NULL
CD40	NULL
engagement	NULL
by	NULL
CD4OL	NULL
expressed	NULL
by	NULL
an	NULL
activated	NULL
CD4*	NULL
T	NULL
cell	NULL
and	NULL
exposure	NULL
to	NULL
T	NULL
cell-derived	NULL
cytokines	NULL
.	NULL

BCR	NULL
coengagement	NULL
by	NULL
Ag	NULL
as	NULL
well	NULL
as	NULL
IL-6	NULL
and	NULL
IL-12	NULL
secreted	NULL
by	NULL
an	NULL
activated	NULL
dendritic	NULL
cell	NULL
inhibit	NULL
the	NULL
expression	NULL
of	NULL
CD30	NULL
by	NULL
this	NULL
GC	NULL
B	NULL
cell	NULL
.	NULL

In	NULL
the	NULL
lower	NULL
limb	NULL
,	NULL
a	NULL
naive	NULL
B	NULL
cell	NULL
is	NULL
activated	NULL
by	NULL
a	NULL
CD4*CDA4O0L*	NULL
T	NULL
cell	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
BCR	NULL
coengagement	NULL
by	NULL
Ag	NULL
complexes	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
a	NULL
dendritic	NULL
cell	NULL
and	NULL
,	NULL
therefore	NULL
,	NULL
expresses	NULL
CD30	NULL
.	NULL

In	NULL
this	NULL
non-Ag-selected	NULL
B	NULL
cell	NULL
,	NULL
CD40L-induced	NULL
switching	NULL
to	NULL
IgG	NULL
,	NULL
IgA	NULL
,	NULL
or	NULL
IgE	NULL
is	NULL
negatively	NULL
modulated	NULL
through	NULL
CD30	NULL
engagement	NULL
by	NULL
CD30L	NULL
expressed	NULL
on	NULL
either	NULL
a	NULL
CD4¢*	NULL
or	NULL
a	NULL
CD8*	NULL
T	NULL
cell	NULL
.	NULL

Immunity	NULL
.	NULL

Author	NULL
manuscript	NULL
;	NULL
available	NULL
in	NULL
PMC	NULL
2015	NULL
October	NULL
26	NULL
.	NULL

